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ABSTRACT 
  Breast cancer is the leading cause of cancer-related death among women 
worldwide. Evidence is also mounting that circadian disruption (CD) is probably 
carcinogenic to humans and is linked to breast cancer development. 
  The aim of this thesis is to provide new insights into the epigenetic links involved 
in CD-induced breast cancer. The results presented here show for the first time that CD 
induces expression changes in breast cancer-relevant and potentially circadian-relevant 
miRNAs in mammary tissues. Moreover, the results also show that long-term CD can 
potentially cause gene expression changes on a large enough scale to influence breast 
cancer-relevant signaling pathways. 
  These findings align with previous studies that have shown that CD is a warranted 
concern in breast cancer development, and that the initiation of this process may be 
linked to aberrant CD-induced miRNA activity in the mammary tissues. 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
  First and foremost, I would like to thank my parents, Ewa and Andrzej Kochan, 
for their support, encouragement, and patience. Dziękuję. 
 
  I would like to thank Dr. Olga Kovalchuk for the opportunity to advance my 
science career as a student in her laboratory. The experience and knowledge that I have 
gained in your lab has given me the confidence and skill set to pursue future scientific 
endeavors.    
 
  I would also like to thank my committee members, Dr. Theresa Burg and Dr. 
Robert McDonald, for their support and guidance throughout my Master’s program. 
 
  Last, but not least, I would like to thank my colleagues from both Kovalchuk 
laboratories for their guidance, support, and most importantly, their friendship. Special 
thanks to Dr. Slava Ilnytsky, Dr. Andrey Golubov, and Rocio Rodriguez Juarez for 
always being there to provide advice and answering my many, many questions.
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
 
ABSTRACT……………………………………………………………………………...iii 
Acknowledgements……………………………………………………………………….iv 
Table of Contents………………………………………………………………………….v 
List of Tables…………………………………………………………………………….vii 
List of Figures……………………………………………………………………………vii 
List of Abbreviations……………………………………………………………………..ix 
CHAPTER 1: CIRCADIAN DISRUPTION AND BREAST CANCER: AN EPIGENTIC 
LINK? …………………………………………………………………………………….1 
    Abstract…………………………………………………………………………………2 
    Introduction……………………………………………………………………………..3 
    Circadian Rhythms……………………………………………………………………...4 
         Surpachiasmatic Nucleus……………………………………………………………4 
         Melatonin……………………………………………………………………………7 
         Clock Genes…………………………………………………………………………9 
         Clock Genes and Breast Cancer……………………………………………………10 
    Epigenetics…………………………………………………………………………….14 
         DNA Methylation………………………………………………………………….14 
         DNA Methylation and Breast Cancer……………………………………………...15 
         DNA Methylation and Circadian Rhythms………………………………………...19 
         MicroRNAs………………………………………………………………………...21 
         MicroRNAs and Breast Cancer……………………………………………………24 
         MicroRNAs and Circadian Rhythms………………………………………………26 
    CD-Induced Breast Cancer: An Epigenetic Link? ……………………………………28 
    Future Directions and Conclusions……………………………………………………31    
    Present Study and Hypothesis…………………………………………………………33 
CHAPTER 2: CIRCADIAN DISRUPTION-INDUCED MICRORNAOME 
DEREGULATION IN RAT MAMMARY TISSUES…………………………………..36  
    Abstract………………………………………………………………………………..37 
    Introduction……………………………………………………………………………38 
    Materials and Methods………………………………………………………………...40 
         Animal model and circadian-disruption paradigm………………………………...40 
         Total RNA extraction………………………………………………………………42     
         Small RNA sequencing and bioinformatics analysis………………………………43 
         Small RNA qRT-PCR……………………………………………………………...44 
         Western Blot Analyses……………………………………………………………..45 
         Statistical Analyses………………………………………………………………...46 
    Results…………………………………………………………………………………46 
         Circadian disruption causes aberrant expression of a broad range of miRNAs, and 
the changes are linked to an early time point in the circadian cycle……………………..46 
         Validation of sequencing results through qRT-PCR verifies miR-127 expression..48 
         Circadian-disruption-induced changes in miRNA expression in the two-week 
chronic ZT06 group correlated to aberrant levels of breast-cancer-relevant proteins…...48 
    Discussion……………………………………………………………………………..50 
CHAPTER 3: CIRCADIAN DISRUPTION-INDUCED SIGNALLING PATHWAY 
vi 
 
DEREGULATION IN RAT MAMMARY TISSUES…………………………………..69 
    Abstract………………………………………………………………………………..70 
    Introduction……………………………………………………………………………71 
    Materials and Methods………………………………………………………………...73 
         Animal model and circadian-disruption paradigm………………………………...73 
         Total RNA extraction ……………………………………………………………...75     
         Gene expression sequencing and bioinformatics analysis…………………………76 
         qRT-PCRs………………………………………………………………………….77 
         Statistical Analyses………………………………………………………………...78 
    Results…………………………………………………………………………………78 
         Circadian disruption results in the differential expression of a broad range of genes 
linked to breast cancer in the two-week chronic ZT19 group…………………………...78 
         The CD-induced gene expression changes in the two-week chronic ZT19 group 
correlated to disturbances in breast cancer related pathways……………………………79 
        qRT-PCR validation produces the same expression trends, but not significant 
differences………………………………………………………………………………..80 
    Discussion……………………………………………………………………………..80 
CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS……………………..95  
    Future Directions…………………………………………………………………….100 
REFERENCES…………………………………………………………………………102 
APPENDIX A: Supplementary Figures………………………………………………...114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES 
 
Table 2.1: Circadian disruption induces changes in a broad range of breast cancer 
relevant miRNAs………………………………………………………………………...59  
 
Table 2.2: Circadian disruption induces potentially aberrant miRNA expression 
patterns…………………………………………………………………………………...64 
 
Table 3.1: Circadian disruption induces changes in gene expression…………………...86 
 
Table 3.2: Stability data for the qRT-PCR results………………………………………94 
 
LIST OF FIGURES 
Figure 1.1: Overview of the two interlocking circadian clock regulatory feedback 
loops……………………………………………………………………………………...35 
 
Figure 2.1: Circadian disruption causes changes in miRNA expression in both the acute 
and chronic groups. ……………………………………………………………………...60 
 
Figure 2.2: Chronic circadian disruption causes significant changes in miRNA 
expression in the ZT06 groups. ………………………………………………………….61 
 
Figure 2.3: Acute circadian disruption causes significant changes in miRNA expression 
in the 24-hour acute ZT06 group.………………………………………………………..62 
 
Figure 2.4: Chronic and acute circadian disruption causes no significant changes in 
miRNA expression in all the ZT19 groups………………………………………………63 
 
Figure 2.5: Circadian disruption causes lowered expression of miRNAs 146a and 146b, 
and increased expression of activated NFκB…………………………………………….65 
 
Figure 2.6: Circadian disruption causes decreased expression of miR-127, and increased 
expression of Tudor-SN and BCL6……………………………………………………...66 
 
Figure 2.7: Circadian disruption causes increased expression of STAT3………………67 
 
Figure 2.8: Circadian disruption causes increased expression of DNMT1……………..68 
 
Figure 3.1: Heat map cluster of the Illumina gene sequencing results………………….85 
 
Figure 3.2: Circadian disruption causes large scale gene expression changes in the 2-
week chronic ZT19 group. ………………………………………………………………87 
 
Figure 3.3: Circadian disruption causes changes to disease related and breast cancer 
relevant pathways in the 2-week chronic ZT19 group…………………………………88 
viii 
 
Figure 3.4: Circadian disruption induced changes to the base excision repair pathway..89 
 
Figure 3.5: Circadian disruption induced changes to the homologous recombination 
pathway…………………………………………………………………………………..90 
 
Figure 3.6: Circadian disruption induced changes to the mismatch repair and nucleotide 
excision repair pathways…………………………………………………………………91 
 
Figure 3.7: Circadian disruption induced changes to the p53 signaling pathway………92 
 
Figure 3.8: qRT-PCR and Illumina sequencing data for the Cdk1 and Pdk4 genes…….93 
 
Figure 3.9: qRT-PCR and Illumina sequencing data for the Nusap1 gene……………...94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF ABBREVIATIONS 
5-aza – 5-aza-2`deoxycytidine 
Ago – argonaute 
AKT – protein kinase B 
ALU – arthrobacter luteus 
BER – base excision repair 
BC – breast cancer 
BCL – B-cell lymphoma 
BID – BH3-interacting domain death agonist 
BMAL1 – brain and muscle ARNT-like protein 1 
BRCA1 – breast cancer 1, early onset 
BTG2 – BTG  family member 2 
c-Myc – myc avian myelocytomatosis viral oncogene homolog 
CaM – calmodulin 
cAMP – cyclic adenosine monophosphate 
CSC – cancer stem cells 
CD – circadian disruption 
CDK – cyclin dependent kinase 
CHK – check point kinase 
CKIδ – casein kinase one delta  
CKIε – casein kinase one epsilon 
CLOCK – circadian locomotor output cycles kaput 
CpG/CG – cytosine guanine dinucleotides 
CRY – crytpochrome 
DKK3 – dickkopf WNT signaling pathway inhibitor 3 
DLX5 – distal-less homeobox 5 
DMBA – 7,12-Dimethylbenz[a]anthracene 
DDR – DNA damage response 
DNA – deoxyribonucleic acid 
DNMT – DNA methyltransferase 
DSB – double strand breaks 
G1 – growth 1/gap 1 
G2 – pre-mitotic  
E2 – estradiol 
ECL – enhanced chemiluminescence  
EGF – epidermal growth factor 
EMT – epithelial-to-mesenchymal transition 
ER/ESR – estrogen receptor 
ERBB2 – erb-b2 receptor tyrosine kinase  
ERE – estrogen response element 
x 
 
FxR – fragile X mental retardation protein 
HER2 – human epidermal growth factor receptor 2 
HOXA5 – homeobox A5 
HR – homologous recombination 
IGF – insulin-like growth factor 1 
JAK – Janus kinase 
LAN – light at night 
LINE-1 – long interspersed nucleotide element-1 
MBD – methyl CpG-binding domain 
MeCP2 – methyl CpG binding protein 2 
miRNA/miR – microRNA 
MLT – melatonin 
MMP-2 – matrix metalloproteinase-2 
MMR – mismatch repair 
MRE – meiotic recombination homolog 
MRN – MRE11-RAD50-NBN complex 
mRNA – messenger RNA 
mTOR – mammalian target of rapamycin 
NER – nucleotide excision repair 
NF-κB – nuclear factor kappa-light-chain-enhancer of activated B cells 
nt – nucleotides 
NUSAP1 – nucleolar and spindle-associated protein 1  
oncomiR – oncogenic miRNA 
P-bodies – processing bodies 
PACT – protein activator of the interferon-induced protein kinase 
PAGE – polyacrylamide gel electrophoresis  
PAIP2A – PABP interacting protein 2A 
PCR – polymerase chain reaction 
PDCD4 – programmed cell death 4 
PER – period 
PI3K – phosphatidylinositide 3-kinases 
PKC – protein kinase C 
PLAU/uPA – protease urokinase-type plasminogen activator  
PMD – partially methylated domain 
PR – progesterone receptor 
pre-miRNA – precursor miRNA 
pri-miRNA – primary miRNA 
PS – photoperiod shifting 
PTEN – phosphatase and tensin homolog 
PVDF – polyvinylidene difluoride  
xi 
 
qPCR – real time PCR 
RASSF1A – ras association domain-containing protein 1 
RIN – RNA integrity number  
RISC – RNA-induced silencing complex 
RNA – ribonucleic acid 
RT-PCR – reverse transcription PCR 
S-phase – synthesis phase 
SCN – suprachiasmatic nucleus 
SDS – sodium dodecyl sulfate 
SEM – standard error of the mean 
SNP – single nucleotide polymorphisms 
SOX2 – sex determining region Y-box 2 
STAT – signal transducer and activator of transcription 
TAM – tamoxifen  
TP/p – tumor protein 
TRPS1 – trichorhinophalangeal syndrome I 
TSA – trichostatin 
TudorSN – tudor staphylococcal nuclease 
ROR – retinoid-related orphan receptors  
RORE – retinoid-related orphan receptors element 
UTR – untranslated region 
WEE1 – WEE1 G2 checkpoint kinase 
WGSBS – whole genome shotgun bisulfite sequencing 
WIF1 – wnt inhibitory factor 1 
Wnt – wingless integrated signaling pathway 
ZEB – zinc finger E-box binding homeobox 
ZT – zeitgeber time  
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1: BREAST CANCER AND CIRCADIAN DISRUPTION: AN 
EPIGENTIC LINK? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 has been submitted as: 
Kochan, D.Z. and Kovalchuk, O. Breast cancer and circadian disruption: An epigenetic 
link? Oncotarget. Accepted April 2015 pending minor revisions. 
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ABSTRACT 
  Breast cancer is already the most common malignancy affecting women 
worldwide, and evidence is mounting that breast cancer induced by circadian disruption 
is a warranted concern. Numerous studies have investigated various aspects of the 
circadian clock in relation to breast cancer, and evidence from these studies indicates that 
melatonin and the core clock genes can play a crucial role in breast cancer development.  
Even though epigenetics has been increasingly recognized as a key player in the etiology 
of breast cancer and linked to circadian rhythms, and there is evidence of overlap 
between epigenetic deregulation and breast cancer induced by circadian disruption (CD), 
only a handful of studies have directly investigated the role of epigenetics in CD-induced 
breast cancer. This review explores the circadian clock and breast cancer, and the 
growing role of epigenetics in breast cancer development and circadian rhythms. We also 
summarize the current knowledge and next steps for the investigation of the epigenetic 
link in CD-induced breast cancer.     
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INTRODUCTION 
  Breast cancer (BC) is currently the most common malignancy affecting women 
worldwide. It accounts for 25% of all cancers in women and caused 522,000 deaths 
worldwide in 2012 (IARC, 2012). Breast cancer is also present in human males, with 
males having poorer outcomes due to delays in diagnosis (Giordano et al., 2004). 
Estimates by the American Cancer Society indicate that there will be around 2350 new 
cases of male invasive breast cancer in the United States in 2015 
(AmericanCancerSociety, 2015). The development of breast cancer emerges through a 
multi-step process, encompassing progressive changes from a normal cell to hyperplasia, 
carcinoma in situ, invasive carcinoma, and metastasis, with the cancer either originating 
in the milk ducts, milk-producing lobules, or connective tissues (Abeloff et al., 2008; 
Shackney and Silverman, 2003; Simpson et al., 2005). Breast cancer tumours also vary in 
gene expression patterns and other characteristics, resulting in different classifications 
and treatment options.  
  Currently, breast cancers are separated into two main classes based on specific 
phenotypes. The two main classes are dependent on the hormone status of the cancer with 
estrogen receptor (ER) and progesterone receptor (PR) positive cancers being part of the 
luminal class, and the ER and PR negative cancers being distinguished as non-luminal 
(Britten et al., 2013). The luminal status of the breast cancer is then combined with the 
expression status of the erb-b2 receptor tyrosine kinase (ERBB2) gene, a proto-oncogene 
which encodes for the human epidermal growth factor receptor 2 (HER2) protein, in 
order to determine if an overabundance of HER2 plays a role in tumour progression and 
to classify the cancer into one of four specific groups: luminal A (group 1), luminal B 
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(group 2), HER-2 positive (group 3), and basal-like/triple negative (group 4) (Britten et 
al., 2013). Groups 1 and 2 are the hormone positive breast cancers, with luminal A being 
HER2 negative and luminal B being HER2 positive. Groups 3 and 4 are the non-luminal 
cancers, and as the group names suggest, the HER2-positive group only expresses HER2 
and the triple negative group is negative for all three of the phenotypes tested.  
  Based on the four-group classification system discussed, breast cancer patient 
treatment options have become more specific and efficient, and the prognosis of patients 
has become better and more accurate. In terms of the luminal breast cancers, these 
tumours are less aggressive, lead to a better prognosis, and respond to more treatment 
options. For example, Tamoxifen (TAM), an ER antagonist drug, is the current treatment 
choice for groups 1 and 2 at any stage in pre- and post-menopausal women (Li et al., 
2013; Mourits et al., 2001). However, TAM treatment is not a valid option for groups 3 
and 4 because there is no ER expression in these tumours, but non-luminal breast cancers 
are more aggressive, offer a poorer prognosis, and respond to fewer treatment options 
(Gadducci et al., 2005; Li et al., 2013). As a result, a potential approach to treating non-
luminal breast cancers is to reactivate ER activity through drugs such as 5-aza-
2`deoxycytidine (5-aza) or Trichostatin A (TSA), and then apply TAM treatment or 
chemotherapy (Jang et al., 2004; Li et al., 2013; Yang et al., 2001). Although this 
approach may not be as efficient and proven as regular hormonal treatment, it represents 
a step in the right direction that was made possible by investigating the characteristics of 
different breast cancers.   
  In 2007, the International Agency for Research on Cancer concluded that 
“shiftwork that involves circadian disruption is probably carcinogenic to humans” 
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(Hansen and Stevens, 2012). Recent case studies have supported this claim by providing 
indirect evidence that shift workers are at higher risk of developing breast cancer. 
Specifically, studies found that work after midnight significantly increased the risk of 
breast cancer in women when compared to day work, that the risk increased with the 
duration and accumulation of overnight shifts, and that rotating shifts between day and 
night is more disruptive than permanent night work (Hansen and Stevens, 2012; 
Knutsson et al., 2013). These case study findings, in combination with the fact that one 
third of the Canadian labour force is not working a regular daytime shift and that shift 
work may cause a higher prevalence of ER negative breast cancer, warrants further 
investigation into the mechanisms underlying breast carcinogenesis due to circadian 
disruption (CD) (Demers et al., 2010; Rabstein et al., 2013). By investigating the 
characteristics and mechanisms involved in CD-induced breast cancer, valuable insights 
and knowledge may materialize, thus potentially allowing for different treatment options 
to emerge and improving the prognosis of patients. 
CIRCADIAN RHYTHMS 
  A circadian rhythm is any biological process that displays an endogenous, 
entrainable oscillation of approximately 24 hours, with these biological processes being 
controlled by a circadian system that is organized in a hierarchical manner.  
Suprachiasmatic Nucleus  
  The paired suprachiasmatic nucleus (SCN) of the anterior hypothalamus acts as 
the master oscillator of circadian rhythms by regulating downstream peripheral oscillators 
via endocrine and neural signals (Reppert and Weaver, 2002). This master oscillator is 
composed of two distinct regions, a shell and a core (Antle and Silver, 2005). The shell 
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region exhibits uniform oscillations of activity, is not immediately responsive to photic 
stimulation, and can maintain an approximate 24 hour pattern of activity in the absence of 
environmental stimuli (Abrahamson and Moore, 2001; Welsh et al., 2010). Unlike the 
shell, the core does not display synchronized, rhythmic patterns of activity in the absence 
of an external input (Butler and Silver, 2009). Instead, the core is externally synchronized 
by environmental light through non-visual, photic retinal ganglion cells (Abrahamson and 
Moore, 2001; Haus and Smolensky, 2013; Silver et al., 1996). Working together, the core 
interprets and analyzes information regarding the time of day and entrains the oscillator 
present within the shell (Antle and Silver, 2005). The shell then regulates the output of 
the SCN, resulting in the organization of bodily processes on an environmentally 
synchronized schedule for optimal performance (Antle and Silver, 2005; Welsh et al., 
2010). 
   In humans, many biochemical processes, such as hormone secretion, cell cycle, 
apoptosis, and gene expression, are entrained on a regular 24-hour rhythm by daily 
periods of light exposure (Stevens, 2009). Repeated unnatural exposure to light during 
the dark phase of the circadian cycle, such as through shift work, disrupts the activity of 
the SCN and inhibits synchronizing of the circadian clock to the proper light-dark cycle 
(Monsees et al., 2012). Although the SCN has the capacity to adjust to new schedules, 
this adjustment does not occur instantly; instead, it occurs over a certain number of 24-
hour cycles (Haus and Smolensky, 2013). Evidence also shows that the majority of shift 
workers never actually entrain fully to the aberrant light-dark schedule, resulting in 
continuously desynchronized circadian rhythms (Folkard, 2008; Haus and Smolensky, 
2006). Furthermore, peripheral oscillators depend on the SCN for guidance. However, the 
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SCN adapts faster than peripheral oscillators to environmental stimuli, and as a result, 
there is a lag that occurs which causes a desynchronizing between the SCN and the 
peripheral oscillators (Zelinski et al., 2014). During this lag period, a multitude of 
rhythmic events can become disrupted, resulting in circadian phase shifts that can lead to 
complications and disease (Zelinski et al., 2014).  
Melatonin 
  Melatonin (MLT), a pineal hormone that plays a role in the control of sleep, is 
directly linked to circadian rhythm activity through the master oscillator, the 
suprachiasmatic nucleus. As a result of this integration, not only does the concentration 
of MLT fluctuate during a circadian cycle, but the ability of melatonin to influence the 
SCN also changes (Korkmaz et al., 2009). Through a biological timing signal that is 
internally driven by the central pacemaker in the SCN, MLT is abundant during the night 
and almost completely absent during the day, with sleep not being necessary to initiate 
the increase in melatonin levels, but complete darkness being an absolute requirement 
(Arendt, 2006; Blask, 2009). Therefore, aberrant exposure to light at nighttime can result 
in lower melatonin levels and potential complications.  
 Evidence shows that melatonin appears to be involved in cancer development and 
growth. In experimental rat models of chemical carcinogenesis, the physiological 
melatonin signal suppresses the initiation phase of tumourigenesis by suppressing the 
damage and alterations caused by DNA adducts (Blask, 2009; Reiter, 2004). The ability 
of melatonin to suppress DNA adduct damage is believed to be due to melatonin acting 
as a potent free-radical scavenger and/or promoting repair of DNA once damage has 
occurred (Blask, 2009; Reiter, 2004). Studies also show that at nocturnal concentrations, 
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melatonin may exhibit biochemical and molecular oncostatic actions. In a rat MCF-7 
breast cancer cell xenograft study, evidence showed that constant exposure to light 
resulted in deregulation of the circadian MLT rhythm, and that the tumour xenografts 
associated with constant light exposure showed significantly increased growth when 
compared to the light-dark groups (Blask et al., 2003). Another study, utilizing DMBA 
induced mammary adenocarcinomas in female rats, illustrated that a constant dim light 
during the dark phase of the circadian cycle caused higher rates of tumour growth and 
lower levels of survival (Cos et al., 2006).  
  A possible explanation for the nocturnal, light-induced tumour growth may be 
that lower levels of MLT cause increased metabolism of fatty acids and aberrations in 
cancer-dependent pathways. For example, melatonin can cause receptor-mediated 
inhibition of cyclic adenosine monophosphate (cAMP), resulting in downregulation of 
the transcriptional expression of ERα in human breast cancer cells and lower fatty acid 
metabolism by tumour cells through decreased fatty acid transport (Blask, 2009; Blask et 
al., 2003; Sauer et al., 2001). Calmodulin (CaM) activity, which plays a role in breast 
cancer tumour development by suppressing apoptosis and increasing survival through 
EGF-initiated activation of protein kinase B (Akt), is also lowered by melatonin activity 
through binding of the pineal hormone to CaM and by melatonin stimulating 
phosphorylation of CaM through protein kinase C α (PKCα) (Benitez-King et al., 1993; 
Coticchia et al., 2009; Soto-Vega et al., 2004). Further studies have also shown that 
human breast cancer xenografts exhibit a day-night rhythm of tumour proliferation, fatty 
acid uptake, metabolism, and signal transduction activity, all believed to be driven by the 
nocturnal, circadian rhythm melatonin signal (Blask, 2009; Reiter, 2004). 
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Clock Genes  
   In mammals, two to ten percent of all gene expression is rhythmic, and these 
clock genes, located in peripheral oscillators and found in almost all nucleated cells of the 
human body, regulate practically every biological process and function in a time-specific 
manner to help maintain circadian rhythms (Reppert and Weaver, 2002; Storch et al., 
2002). Aiding in the maintenance of the circadian clock, the core clock genes function 
through two interlocking regulatory feedback loops driven by the genes CLOCK/Npas2, 
Bmal1, Period (Per) and Cryptochrome (Cry) (Figure 1.1). In one regulatory loop, two 
transcriptional activators, BMAL1 (brain and muscle ARNT-like protein 1) and CLOCK 
(circadian locomotor output cycles kaput), form CLOCK/BMAL1 heterodimers in the 
nucleus where they activate the expression of the Per and Cry genes by binding to E-box 
promoter sequences (Figure 1.1). In the cytoplasm, the PER and CRY proteins form 
complexes with each other, move into the nucleus, and inhibit the activity of the 
CLOCK/BMAL1 heterodimers, thus causing transcription of the Per and Cry genes to 
stop (Figure 1.1). In the other regulatory loop, the expression of the Bmal1 gene is 
controlled through CLOCK/BMAL1 heterodimer formation in the nucleus (Figure 1.1). 
These heterodimers bind to the E-box promoter sequences of genes that encode the 
retinoic acid-related orphan nuclear receptors (ROR), Rev-erbα and Roraα; The Rev-erbα 
and Roraα proteins then compete for the ROR element (RORE) in the Bmal1 promoter 
and suppress or activate Bmal1 expression, respectively (Figure 1.1).  
 Through utilization of these circadian feedback loops, the precision of the 
mammalian clock is controlled through post-translational modifications (Ko and 
Takahashi, 2006). Casein kinase one epsilon (CKIε) and casein kinase one delta (CKIδ), 
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are the two main kinases responsible for the phosphorylation of the PER and CRY 
proteins (Reppert and Weaver, 2002). Through the activity of these kinases, by the end of 
a regular circadian cycle, the PER1 and PER2 proteins have almost entirely undergone 
degradation, thereby preventing CLOCK/BMAL1 suppression in the nucleus and 
initiating the start of the next circadian cycle (Eide et al., 2005). Nuclear entry of the PER 
and CRY proteins also acts as a vital checkpoint for progression of the circadian cycle, 
with a co-dependency existing between the two proteins (Reppert and Weaver, 2002). 
The presence of CRY1 and PER2 interaction in the cytoplasm results in PER2 stability 
by preventing its degradation through CKIε phosphorylation, and thus permits nuclear 
translocation and suppression of the CLOCK/BMAL1 heterodimer (Figure 1.1). 
Alterations to the balance between the CRY and PER proteins can therefore lead to 
changes in the circadian cycle. For example, the Tau mutation in the CKIε gene leads to 
altered levels of phosphorylation of PER proteins, resulting in a shortened circadian 
length (Lowrey et al., 2000).  Furthermore, Per1 and Per2 respond and adapt faster than 
Cry1 to circadian disruption, and as a result, circadian disruption can induce internal 
phase shifts within the circadian clock (Nakamura et al., 2005). 
Clock Genes and Breast Cancer  
  In addition to helping regulate circadian oscillations, the core clock genes have 
been shown to influence cancer related mechanisms such as cell proliferation, apoptosis, 
cell cycle, and tumour-suppressor genes. Studies have shown that overexpression of Per1 
and Per2 inhibits the growth of various cancer cells. Period1 plays a role in cell apoptosis 
in human cancer cells, with its down-regulation stopping apoptosis and its overexpression 
increasing DNA damage-induced apoptosis (Gery et al., 2006). The Per2 gene has been 
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shown to act as a tumour suppressor in luminal breast cancers by linking the circadian 
oscillator system to the ERα function (Gery et al., 2007). Human Per2 is estradiol (E2) 
inducible in mammary cells, causing Per2 expression to lower ERα activation through 
the consumption of E2 (Haus and Smolensky, 2013). Since ER activation through E2 
results in DNA adduct formation, mammary cell proliferation, and genotoxic waste, the 
reduction in ERα activation by Per2 expression results in an oncostatic effect (Parl et al., 
2009).  
   The overexpression of CLOCK has been linked to increased proliferation in 
luminal breast cancer cells (Xiao et al., 2014). This oncogenic influence of CLOCK is 
likely associated with estrogen-estrogen receptor α (E2- ERα) signaling, with E2 
promoting the binding of ERα to estrogen response elements (EREs) of the CLOCK 
promoter and increasing transcription (Xiao et al., 2014). Numerous single nucleotide 
polymorphisms (SNPs) in the CLOCK gene have been correlated with increased breast 
cancer risk (Hoffman et al., 2010a). Interestingly, 67% of the SNPs were associated with 
non-luminal breast cancers, indicating that CLOCK expression most likely plays a role in 
both luminal and non-luminal BCs (Hoffman et al., 2010a). The same study also showed 
that CLOCK knockdown results in increased expression of various tumour suppressor 
genes and decreased expression of multiple oncogenes, indicating an oncogenic influence 
by CLOCK on breast cancer development (Hoffman et al., 2010a).       
  Unlike CLOCK, BMAL1 has been reported as having oncostatic effects in cancer 
development. Specifically, BMAL1 has been shown to suppress cancer cell invasion by 
antagonizing the oncogene B-cell lymphoma-w (Bcl-w), thus suppressing matrix 
metalloproteinase-2 (MMP-2) accumulation and blocking the PI3K-AKT-MMP2 
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signaling pathway (Jung et al., 2013). Furthermore, loss of Bmal1 expression has been 
shown to result in lower transcript levels of Per1 and Per2, and increased protein levels 
of cyclin D1 (Zeng et al., 2010). The cyclin D1 protein is involved in promoting 
transition from the G1 to the S-phase in the cell-cycle by binding to cyclin-dependent 
kinase 4 (CDK4) or CDK6 proteins, and its overexpression enhances the activity of ERα 
and counteracts the breast cancer-suppressor gene breast cancer 1, early onset (BRCA1) 
(Wang et al., 2005). In mice and human cancer patients, overexpression of cyclin D1 is 
associated with mammary tumourigenesis and poor medical prognosis, respectively (Fu 
et al., 2002; Haus and Smolensky, 2013).       
  As an extension of the influences of CLOCK and BMAL1 on cancer 
development, the CLOCK/BMAL1 heterodimer has been shown to regulate cell-cycle 
genes that are involved in breast cancer progression (Haus and Smolensky, 2013). This 
regulation occurs in an oncogenic manner through the activation of WEE1 G2 checkpoint 
kinase (WEE1), and an oncostatic manner through the suppression of myc avian 
myelocytomatosis viral oncogene homolog (c-MYC) (Chen-Goodspeed and Lee, 2007; 
Fu et al., 2002; Haus and Smolensky, 2013; Matsuo et al., 2003). In breast cancer cells, 
the G1 cycle checkpoint is often aberrantly regulated, allowing cells with DNA damage to 
enter the S phase (Vriend et al., 2013). When this occurs, cancer cells rely on the G2 
check point for damage repair before entering mitosis (Vriend et al., 2013). Over 
expressed in breast cancer cells, the WEE1 protein is a nuclear kinase that helps regulate 
transition from the G2 phase to mitosis by inhibiting the activity of the CDK1 protein, 
thus increasing DNA repair in cancer cells prior to mitosis (Parker and Piwnica-Worms, 
1992; Vriend et al., 2013).Overexpressed c-Myc causes increased cell proliferation 
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through cyclin activity and lowered apoptosis through Bcl-2 activity, with c-Myc 
overexpression eventually leading to hyperplasia and tumour development (Fu et al., 
2002).  
  Although both the Cry genes may be implicated in breast cancer development, the 
majority of findings thus far have pinpointed Cry2 as playing a more prominent role. 
In a study investigating the potential significance of Cry2 in breast cancer development, 
experimenters identified SNPs in the Cry2 gene as potential biomarkers for increased risk 
of breast cancer, with the variants having a stronger association with non-luminal breast 
cancers (Hoffman et al., 2010b). The results also illustrated that the degree of Cry2 
expression can vary between breast cancer types, with the non-luminal breast cancers 
having higher levels of Cry2 expression when compared to luminal breast cancers 
(Hoffman et al., 2010b). Finally, CRY2 knockdown in MCF-7 cancer cells resulted in 
aberrant regulation of cell differentiation, proliferation, motility, angiogenesis, and 
apoptosis, thus suggesting a tumour-suppressor role for CRY2 in breast cancer 
development (Hoffman et al., 2010b).  
  As discussed thus far, there is clear evidence connecting the circadian clock and 
its components to breast cancer development through hormone activity and the influence 
of core clock genes. However, there is another area of study that may provide the crucial 
link in CD-induced breast cancer.    
EPIGENETICS 
  Epigenetics is the study of heritable changes in gene expression or cellular 
phenotype by mechanisms that do not involve direct changes to the DNA sequence. Two 
examples of epigenetic mechanisms are DNA methylation and RNA associated silencing. 
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DNA Methylation 
  The biochemical process of DNA methylation involves the addition of a methyl 
group to the 5` carbon of the cytosine nucleotide (Klose and Bird, 2006). Cytosine DNA 
methylation is one of the most widely studied and known epigenetic mechanisms (Klose 
and Bird, 2006). DNA methylation plays a crucial role in normal cell development, cell 
proliferation, and maintenance of genome stability (Klose and Bird, 2006). In mammals, 
DNA methylation is mediated by DNA methyltransferase enzymes. DNA 
methyltransferase 1 (DNMT1) is the major enzyme involved in maintenance DNA 
methylation and is responsible for copying DNA methylation patterns to daughter strands 
during DNA replication (Liang et al., 2002). DNA methyltransferase 3a (DNMT3a) and 
DNMT3b act as de novo methyltransferases that target unmethylated and hemimethylated 
sites, and are responsible for DNA methylation patterns early in development (Goll and 
Bestor, 2005). Finally, although DNMT3L has no methyltransferase activity, it interacts 
with DNMT3a and 3b to help establish maternal methylation imprints and appropriate 
expression of maternally imprinted genes (Hata et al., 2002).   
  The activity of DNA methyltransferases mostly occurs in the context of CG 
dinucleotides (CpG), with about 60‒80% of CpG cytosines being methylated in mammals 
(Weber and Schubeler, 2007). Hypermethylation of CpG dinucleotides, which is over 
methylation of DNA, is linked to genomic instability due to silencing of DNA repair 
genes, silencing of tumour-suppressor genes, and compaction of chromatin (Jovanovic et 
al., 2010). Hypomethylation of CpG dinucleotides, which is the absence of cytosine 
methylation, has been linked to gene reactivation, chromosomal instability, and up-
regulation of proto-oncogenes (De Smet et al., 2004). The ability of DNA methylation to 
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cause transcriptional repression is achieved through methyl CpG-binding domain (MBD) 
proteins, with these proteins selectively interacting with methylated DNA in order to 
achieve gene silencing (Klose and Bird, 2006). Many genes in mammals also have CpG 
islands that are found close to promoter regions of genes (Merlo et al., 1995). These short 
stretches of DNA, located in the 5`-regions of 60% of all genes, contain high 
concentrations of CpGs, with the methylation status of these islands usually being 
reversed in tumour cells when compared to normal cells for genes that play a role in 
cancer development (Jovanovic et al., 2010). 
DNA Methylation and Breast Cancer 
  In recent years, recognition of the role DNA methylation plays in the etiology of 
breast cancer has increased. In terms of hypermethylation, more than 100 genes have 
been reported to be hypermethylated in breast tumours or breast cancer cell lines, with 
many of these genes playing a role in DNA repair, cell-cycle regulation, apoptosis, and 
metastasis. Among the hypermethylated genes involved in DNA repair are BRCA1 and 
RAD9 Homolog A (RAD9) (Jovanovic et al., 2010). BRCA1 is an extensively studied 
tumour-suppressor gene involved in double-stranded DNA breaks through homologous 
recombination repair in late S and G2 phases of the cell-cycle, while RAD9 is involved in 
base excision repair, mismatch repair, and homologous recombination repair (Jiang et al., 
2013; Lieberman et al., 2011). Some of the hypermethylated genes involved in cell-cycle 
regulation are dickkopf WNT signaling pathway inhibitor 3 (DKK3) and wnt inhibitory 
factor 1 (WIF1), and some of the genes involved in apoptosis are homeobox A5 
(HOXA5) and target of methylation-induced silencing (TMS1) (Jovanovic et al., 2010; 
Veeck et al., 2009). Both WIF1 and DKK3 are Wnt signaling-pathway antagonists, with 
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increased Wnt pathway activity being associated with lowered cell senescence, resistance 
to apoptosis, and increased resistance to anti-cancer therapies (Lamb et al., 2013; Veeck 
et al., 2009). HOXA5 expression increases apoptotic activity in a p53-dependent manner 
and through caspase activity (Chen et al., 2004b). Although the exact mechanism by 
which TMS1 induces apoptosis has not yet been fully elucidated, TMS1 is a proapoptotic 
gene and a sensitive prognostic marker for tumourigenesis (Salminen et al., 2014). 
Hypermethylation of tumour-suppressor genes can also be an early marker in breast 
cancer and be compounded by DNMT activity. For example, hypermethylation of the 
tumour-suppressor gene Ras association domain-containing protein 1 (RASSF1A) is an 
early epigenetic event in breast cancer, and it has been shown to increase linearly in 
benign breast tissue of women between 23 and 55 years of age (Euhus et al., 2008). 
 The hypermethylation status of certain genes has also been linked as a predictor 
of hormone receptor development in breast carcinogenesis. DNA methylation of estrogen 
receptor1 (ESR1) and progesterone receptor (PR) promoters has been proposed as a 
mechanism for the development of ER-negative tumours (Ferguson et al., 1995; Lapidus 
et al., 1996; Weigel and deConinck, 1993). A recent clinical study has also shown that 
ERα-promoter hypermethylation has a strong correlation with ER-negative tumours, PR-
negative tumours, and non-luminal tumours (Izadi et al., 2012). Furthermore, another 
study conducted a CpG methylation-pattern analysis on known breast cancer tumour-
suppressor genes in order to correlate methylation status with hormone expression. The 
study found that a combination of reversion-induced LIM (RIL) and cadherin 13 
(CDH13) hypermethylation was strongly correlated with ER- and PR-negative tumours, 
while a combination of high in normal (HIN-1) and RASSFIA methylation was associated 
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with ER- and PR-positive tumours (Feng et al., 2007).  
 Although DNA hypomethylation was the first epigenetic abnormality discovered 
in human tumours, it was somewhat cast into the shadows at the expense of tumour-
suppressor genes and hypermethylation (Ehrlich, 2009; Feinberg and Vogelstein, 1983). 
More widely spread across the genome and associated with repetitive DNA elements, 
DNA hypomethylation was not only ignored, but it was more difficult to pinpoint with 
limited technology (Brena and Costello, 2007; Ehrlich, 2009). However, as scientific 
technologies have continued to improve, the role of DNA hypomethylation in breast 
cancer development has become more illuminated.  
  Among the types of repetitive DNA elements affected by global hypomethylation 
are transposable DNA elements (Hormozdiari et al., 2011). Constituting 11% and 17% of 
the human genome, long interspersed nucleotide element-1 (LINE-1) and Alu are major 
components of these repetitive transposable elements (Lander et al., 2001). Given their 
vast distribution in the genome, these regions are often used as markers for genome-wide 
methylation status (Park et al., 2014). In addition, hypomethylation of these regions has 
been linked to various cancers, with lower methylation causing transcriptional activation, 
retrotransposition, genomic instability, and the decrease in methylation correlating with 
cancer progression (Kitkumthorn and Mutirangura, 2011; Park et al., 2014). In a recent 
study, researchers investigated the link between Alu and LINE-1 hypomethylation and 
breast cancer subtypes (Park et al., 2014). The results showed that Alu hypomethylation 
was correlated with an ER-negative status in invasive breast cancer (IBC), while LINE-1 
hypomethylation was correlated with an ER-negative status and HER2 expression (Park 
et al., 2014). The findings also suggested that LINE-1 hypomethylation is an early event 
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in breast cancer development, while Alu hypomethylation is a late event in breast cancer 
progression, and that lower Alu methylation is associated with poorer disease-free patient 
survival (Park et al., 2014).   
  Among the advances in technology that have allowed for further insight into DNA 
hypomethylation and cancer research is whole-genome shotgun bisulfite sequencing 
(WGSBS). Through the use of this technique, researchers have identified that cystosines 
methylated in the CpG content are almost completely methylated in pluripotent cells, but 
are only partially methylated in somatic cells (Lister et al., 2009). Regions of these 
partially methylated cystosines can be found in nearly 40% of the genome and have been 
classified as partially methylated domains (PMDs) (Lister et al., 2009). Although 
hypomethylation has been traditionally associated with increased gene expression, a 
recent study utilized WGSBS on HER2-positive breast cancer cells and found that global 
hypomethylation is associated with PMDs and gene silencing (Hon et al., 2012). 
Specifically, a significant fraction of genes within the hypomethylated regions showed 
allelic DNA methylation at one allele, and no methylation coupled with repressive 
chromatin marks H3K9me3 or H3K27me3 at the other allele (Hon et al., 2012). The data 
from the experiment also suggest that global hypomethylation in breast cancer likely 
occurs through gradual loss of DNA methylation instead of an active mechanism 
involving demethylating enzymes, and that this gradual global hypomethylation most 
likely triggers the repressive chromatin domains (Hon et al., 2012).    
  Although hypomethylation of transcription regulatory regions in breast cancer is 
rare when compared to hypermethylation of CpG islands, it still does occur. For example, 
the gene encoding protease urokinase-type plasminogen activator (PLAU/uPA) is 
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hypomethylated and over expressed in conjugation with tumour progression in breast 
cancers, with increased uPA expression resulting in increased tumour aggression and 
poor clinical outcome (Annecke et al., 2008; Pakneshan et al., 2004). A high-resolution 
analysis of DNA methylation in breast cancer identified approximately 1500 regions that 
are hypomethylated (Jovanovic et al., 2010; Novak et al., 2008; Shann et al., 2008). 
Taken together, this evidence, in combination with the previous studies discussed, 
indicates that many of these hypomethylated regions may not only contribute to genomic 
instability, but probably contain genes and regulatory sequences involved in breast cancer 
development. 
DNA Methylation and Circadian Rhythms 
   Although not many studies have demonstrated a direct role for DNA methylation 
in the circadian clock, there is evidence suggesting that this epigenetic process may play 
a pivotal role in influencing circadian rhythms. Furthermore, through numerous studies, 
every core clock gene has been identified as being aberrantly methylated in various 
human malignancies (Joska et al., 2014). Among these malignancies is breast cancer, 
with many studies illustrating methylation profiles of the core clock genes that are 
consistent with the aberrant expression patterns previously discussed.     
  A recent study investigated the role of DNA methylation on circadian behaviour 
by using a mouse model system and measuring the effect of altered day length on global 
DNA methylation within the SCN (Azzi et al., 2014). The results showed that mice 
entrained to a 22-hour day had an altered endogenous free-running period (FRP) and 1, 
294 differentially methylated regions when compared to mice entrained to a regular 24-
hour day (Azzi et al., 2014). Among the differentially methylated regions were 
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hypermethylated Per2 and Cry1 promoters, and hypomethylated CLOCK promoters 
(Azzi et al., 2014). To verify further the influence of DNA methylation on FRP, the 
researchers inhibited methylation through the global DNMT inhibitor zebularine, and the 
results showed a significant suppression of FRP changes in the DNMT-inhibited mice. 
Finally, the study illustrated that the aberrant changes to FRP through DNA methylation 
are plastic, with short-day mice entrained back to a regular 24-hour day showing a 
reversion in FRP and DNA methylation levels (Azzi et al., 2014). These results represent 
the first evidence of a direct role for dynamic DNA methylation in the circadian clock, 
and illustrate that the activity of the enzymes catalyzing DNA methylation may be 
influenced by light-dependent induction or repression.  
  As discussed previously, the core clock genes can influence breast cancer 
development through a variety of mechanisms. It is therefore not surprising that promoter 
methylation profiles in breast cancer correlate with the oncogenic and oncostatic actions 
of the core clock genes. For example, a pair of studies showed that all the breast cancer 
types tested had CLOCK-promoter hypomethylation and Cry2-promoter 
hypermethylation when compared to controls (Hoffman et al., 2010a; Hoffman et al., 
2010b).  Another study illustrated that 95% of the breast cancer cells tested in women 
showed aberrant promoter methylation in the Period genes, including Per1- and Per2-
promoter hypermethylation (Chen et al., 2005). The methylation status of the Per genes 
was also linked to increased expression of ERBB2, the gene used to help classify breast 
cancers by type and a prognostic marker that negatively correlates with disease-free 
survival and overall survival (Chen et al., 2005; Tsutsui et al., 2002).  
  Even though there is some evidence for the influence of DNA methylation on 
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circadian rhythms and a consistent promoter-methylation pattern between the core clock 
genes and breast cancer development, skepticism remains about the actual role of DNA 
methylation in circadian rhythms. The question remains whether aberrant DNA 
methylation at clock genes in cancer cells is the cause of circadian disruption, or simply a 
bystander effect of deregulated circadian rhythms. One theory, based on data from 
Neurospora, suggests that the aberrant methylation does not play a causative role and is 
instead a readout (Joska et al., 2014). In either case, the epigenetic influence on CD-
induced breast cancer likely extends into another epigenetic mechanism.       
MicroRNAs 
  Epigenetic control can also be mediated by means of small regulatory RNAs, 
specifically microRNAs (miRNAs). Mature miRNAs are abundant, small, single-
stranded, noncoding RNAs that are potent regulators of gene expression (Hwang and 
Mendell, 2006). Functional (mature) miRNAs can originate from either the exons or 
introns of non-coding genes, or introns of protein-coding genes (Liu et al., 2008a; Liu et 
al., 2008b; Rodriguez et al., 2004). The miRNAs found within the transcripts of other 
genes are under direct transcriptional control of those genes, while miRNAs found within 
intergenic regions are under their own control (Liu et al., 2008a; Liu et al., 2008b). 
Furthermore, miRNAs can be transcribed as a single unit or part of a polycistron, with 
polycistron miRNA expression acting as an efficient mechanism to target a single mRNA 
or to target multiple mRNAs in a signal molecular pathway (Fujita and Iba, 2008; 
Griffiths-Jones et al., 2008; Koturbash et al., 2011).    
  The production and development of mature miRNAs in mammals involves 
multiple steps and numerous proteins and complexes (Ranganna et al., 2013). First, 
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transcription results in primary miRNA (pri-miRNA) in the nucleus, with the leading 
candidate for this pri-miRNA transcription being RNA polymerase (pol) II, but evidence 
showing that RNA pol III may also play a role in some transcripts (Chen et al., 2004a; 
Lee et al., 2004). The RNase III endonuclease Drosha then forms a microprocessor 
complex with the protein DGCR8/Pasha, and digests the pri-miRNA to release a 60‒70 
nucleotide (nt) stem-loop intermediate known as precursor miRNA (pre-miRNA), with 
the base of the stem loop having a 5` phosphate and a two nucleotide 3` overhang that is 
characteristic of RNase III cleavage (Krol et al., 2010; Lee et al., 2002). The pre-miRNA 
is then transported to the cytoplasm by Ran-GTP and the export receptor Exportin5, 
where it undergoes more processing by the enzyme Dicer (Lee et al., 2002). With the 
nuclear processing by Drosha defining one end of the pre-miRNA, the other end is 
processed by Dicer, and as this enzyme is also an RNase III endonuclease, the cleavage 
results in a 5` phosphate and a two nucleotide 3` overhang in place of the stem loop, as 
well as the formation of a mature double stranded miRNA duplex (miRNA:miRNA*) 
(Lee et al., 2003; Lee et al., 2002).  
  In order to control the translation of their target mRNAs, the mature miRNA 
duplex associates with the RNA-induced silencing complex (RISC), which is composed 
of the proteins Argonaute (AGO), protein activator of the interferon-induced protein 
kinase (PACT), fragile X mental retardation protein (FXR), tudor staphylococcal 
nuclease (Tudor-SN), as well as other proteins (Hutvagner and Zamore, 2002). However, 
evidence shows that the miRNA:miRNA* duplex is generally short-lived in comparison 
to the mature single-stranded miRNA, with fragments from the opposing arm (miRNA*) 
being found in much smaller quantities in libraries of cloned miRNAs (Lagos-Quintana et 
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al., 2002; Lim et al., 2003). Although it appears that the AGO protein initiates the 
dissociation of one of the strands, the exact mechanism of strand selection in mammals 
has yet to be elucidated (Koturbash et al., 2011). However, one theory suggests that the 
miRNA* is peeled away and degraded when the miRNA:miRNA* duplex is loaded into 
RISC because the other arm of the duplex has a less-tightly paired 5` end, and as a result, 
it is more thermodynamically favourable to separate the duplex in this manner when 
association with RISC occurs (Khvorova et al., 2003).   
  Once the miRNA-RISC complex is assembled, it then binds to the 3` UTR 
(untranslated region) of target mRNAs, resulting in posttranscriptional down regulation 
of gene expression by one of two mechanisms; mRNA cleavage or translational 
repression. If there is extensive complementarity between the miRNA and the 3` UTR, 
then cleavage of the mRNA occurs (Hutvagner and Zamore, 2002). However, if the 
homology between the miRNA and 3` UTR is not sufficient, productive translation can 
be repressed through processing bodies (P-bodies) (Liu et al., 2005).  In mammals, 
binding is usually not very high in complementarity, so not only is suppression of gene 
expression by miRNAs  usually achieved through inhibitory machinery, but each miRNA 
has numerous targets and can influence the expression of many different genes (Thomson 
et al., 2011).  
MicroRNAs and Breast Cancer  
  The activity of mature miRNAs has an impact on a variety of cancer related 
processes, such as cellular differentiation, proliferation, apoptosis, and genome stability. 
One role by which miRNAs can influence these processes is by acting as oncogenic 
miRNAs (oncomiRs). Among the most well-studied and abundant oncomiRs in various 
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cancers, including breast cancer, is miR-21 (Koturbash et al., 2011). With its expression 
being linked to induction by signal transducer and activator of transcription 3 (STAT-3), 
a protein shown to be overexpressed in breast cancer and linked to various oncogenes, 
miR-21 is often overexpressed as well, resulting in the negative regulation of various 
tumour-suppressor genes (Chen et al., 2013b; Koturbash et al., 2011). Specifically, miR-
21 has been shown to down regulate the expression of the tumour suppressors 
phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) (Frankel 
et al., 2008; Gong et al., 2011).  In breast cancer, PTEN coordinates G1 cell-cycle arrest 
by down regulating the cyclin D1 protein and increasing p27 expression, causing reduced 
cell growth and increased apoptosis (Lu et al., 1999; Weng et al., 2001). PDCD4 inhibits 
CDK1 activity through induction of p21, and loss of PDCD4 is linked to breast cancer 
development (Frankel et al., 2008; Goke et al., 2004). An experiment also showed that 
knockdown of miR-21 in MCF-7 and MDA-MB-231 breast cancer cell lines inhibited in 
vitro growth and migration, as well as in vivo growth (Yan et al., 2011).  
  The expression and activity of oncomiRs can also extend into miRNA clusters. 
For example, the miR-17-92 cluster was among the first miRNA groups discovered to be 
deregulated in various cancers, including breast cancer (Koturbash et al., 2011). 
Containing six miRNAs that are transcribed together as a single polycistron, up-
regulation of these miRNAs has been linked with increased levels of cell proliferation 
and lowered apoptosis (Koturbash et al., 2011). Another oncomiR cluster, the miR-
221/222 tandem, has been linked to ER-negative and triple negative/basal-like breast 
cancers (Stinson et al., 2011; Zhao et al., 2008). In terms of ER-negative breast cancer, 
miR-221/222 was shown to target the 3` UTR of ERα, resulting in lowered ERα protein 
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levels in MCF-7 breast cancer cell lines and increased resistance to TAM treatment (Zhao 
et al., 2008). Triple negative breast cancer is notoriously more aggressive than all the 
other breast cancer groups, and it seems that this aggressiveness may be linked to miR-
221/222 expression (Stinson et al., 2011). Epithelial-to-mesenchymal transition (EMT) is 
the process by which epithelial cells lose the adherent properties and tight junctions that 
keep them in contact with neighbouring cells and gain mesenchymal properties, causing 
gene expression changes within the cells, resistance to apoptosis, and the ability to break 
through the basal membrane and migrate over long distances (Kalluri and Weinberg, 
2009). Evidence shows that the miR-221/222 cluster promotes EMT by repressing 
expression of the trichorhinophalangeal syndrome 1 (TRPS1) protein, which in turn 
results in an increase of the EMT-promoting protein zinc finger E-box binding homeobox 
2 (ZEB2), thus potentially contributing to the more aggressive clinical behaviour of triple 
negative breast cancer (Stinson et al., 2011).  
  In addition to acting as oncomiRs, miRNAs can also act as tumour suppressors. 
Several individual miRNAs have been identified as tumour suppressors in breast cancers. 
Among these are miR-99a and miR-140. MicroRNA 99a overexpression has been shown 
to induce G1 cell-cycle arrest and apoptosis by lowering expression of the mammalian 
target of rapamycin (mTOR) gene, with miR-99a being a potential candidate for use as a 
therapeutic strategy for effectively controlling breast cancer development (Hu et al., 
2014). The transcription factor sex determining region Y-box 2 (SOX2) has been 
reported to be overexpressed in breast cancers and identified as playing a role in the early 
steps of tumour initiation through cancer stem cells (CSCs) (Leis et al., 2012). SOX2  has 
been identified as a target of miR-140, and in ER-α breast cancer cells, estrogen 
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stimulation lowers miR-140 expression through ER-α binding to an ERE flanking the 
mir-140 promoter, thus increasing levels of SOX2 (Zhang et al., 2012). MicroRNA 
tumour-suppressor activity can also extend into miRNA clusters and result in more potent 
regulation than through individual miRNAs. For example, the miR-143/145 cluster has 
been shown to lower ERBB3 protein levels and cause less proliferation and invasion in 
breast cancer cells (Yan et al., 2014). Interestingly, although the miRNAs are still capable 
of causing tumour suppression effects on their own, expression of the miR-143/145 
cluster results in more potent tumour suppression through a synergistic effect (Yan et al., 
2014). 
MicroRNAs and Circadian Rhythms   
  MicroRNA activity has been shown to be associated with circadian rhythms 
through rhythmically regulated miRNAs and through direct influence on the circadian 
cycle. Numerous studies have illustrated that miRNAs oscillate throughout a 24-hour 
circadian day. For example, in Arabidopsis, miRNAs-167, 168, 171, and 398 were shown 
to oscillate, based on environmental light; daytime levels were also reported as higher 
than nighttime levels, and the oscillation of these miRNAs was governed through photic 
control and not an internal clock (Sire et al., 2009). A microarray-based study on mouse 
livers also revealed that over 13% of the probed miRNAs exhibited circadian expression 
patterns (Na et al., 2009). Among these miRNAs were miR-181d and 191, with an 
inversely-correlated expression pattern  being observed between these miRNAs and their 
respective targets, CLOCK and Bmal1 (Na et al., 2009). In another study conducted on 
HeLa cell lines, results showed that the miR-192/194 cluster directly regulates the entire 
Period gene family, with increased expression of the miR192/194 tandem causing 
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lowered expression of the Period genes and a shortening of the circadian cycle (Nagel et 
al., 2009).   
  Of the miRNAs involved in circadian rhythms, miR-132 may potentially play a 
very prominent role, especially when considering the link between circadian rhythms and 
breast cancer. A rodent model experiment showed that miR-132 exhibited oscillatory 
expression in wild-type mice, but not in circadian mutant mice (Cheng et al., 2007). 
Further investigation has also illustrated that miR-132 is induced by light within the SCN 
and that it has the capacity to entrain or reset the circadian clock (Alvarez-Saavedra et al., 
2011). The proposed model suggests that nocturnal light triggers the chromatin 
remodeling gene methyl CpG binding protein 2 (MeCP2), which triggers the transcription 
of various light-responsive genes, including the miR-132 promoter, Per1, Per2, PABP 
interacting protein 2A (Paip2A), and B-cell translocation family member 2 (Btg2) 
(Alvarez-Saavedra et al., 2011). As PERIOD, PAIP2A, and BTG2 protein levels 
increase, PAIP2A and BTG2 levels eventually reach a certain level and Per1 and Per2 
transcription is inhibited by these two proteins (Alvarez-Saavedra et al., 2011).  
Simultaneously, levels of mature miR-132 also increase through miR-132 promoter 
transcription and processing of pri-miRNA into functional miR-132 (Alvarez-Saavedra et 
al., 2011). As levels of mature miR-132 increase, translational repression of its targets 
Mecp2, Paipa2A, and BTG2 eventually occurs, thus restoring homeostasis and resetting 
the induction caused to the circadian clock by nocturnal light (Alvarez-Saavedra et al., 
2011).  
  Interestingly, a recent study has reported that miR-132 levels are lowered in 
breast cancer cells, with miR-132 being identified as a tumour suppressor by inhibiting 
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proliferation, migration, invasion, and metastasis (Zhang et al., 2014). Therefore, by 
extension, the combination of light at night and increased breast cancer risk through shift 
work could potentially result in an aberrant compounded effect through lower miR-132 
expression. Due to increased risk of breast cancer development, miR-132 levels may be 
lowered, and as a result, further nocturnal exposure to light would not only increase 
deregulation of the circadian clock due to the inhibition of homeostasis induced by miR-
132, but also cause lowered oncostatic activity through increased transcriptional 
inhibition of the Period genes by PAIP2A and BTG2.  
  Although none of the research discussed thus far has investigated the link between 
epigenetics, circadian disruption, and breast cancer directly, the fact that the studies 
discussed have dealt with parts of this equation and illustrate potential overlap, 
demonstrates that a potentially substantial link may exist between all three factors. 
CD-INDUCED BREAST CANCER: AN EPIGENETIC LINK? 
  As discussed thus far, numerous studies have investigated the link between 
circadian rhythms and breast cancer, epigenetics and breast cancer, and epigenetics and 
circadian rhythms. However, to date, only a handful of studies have incorporated all three 
factors and investigated the link between CD-induced breast cancer and epigenetic 
modifications. One of these studies incorporated a rodent model to investigate global 
methylation, while the other studies were conducted on human blood samples and 
focused on the influence of shift work on DNA methylation in peripheral blood cells.  
  The rodent model study, conducted to investigate the link between CD-induced 
breast cancer and epigenetic modifications, involved measuring the effect of circadian 
disruption on global methylation levels and the effect of melatonin on this relationship 
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(Schwimmer et al., 2014). Three groups were used in the study: a control group, a light at 
night (LAN) group, and a LAN plus MLT group, with all three of the groups being 
injected with the 4T1-murine breast cancer cell line. The results showed that the LAN 
group had ~30% less global methylation and larger tumour size when compared to the 
control group, while the LAN+MLT group only showed a ~10% decrease in global 
methylation and the smallest amount of tumour growth out of all three groups 
(Schwimmer et al., 2014). These results not only reiterated the important role that MLT 
plays in breast cancer development, but illustrated the important role that DNA 
methylation may play in CD-induced breast cancer and that melatonin levels may be 
linked to the aberrant DNA methylation that is occurring. 
  In a genome methylation analysis of 5,409 CpG sites on nurse blood samples, 
data showed that 3359 (66.4%) of the sites were hypermethylated and 1,816 (33.6%) 
were hypomethylated in long-term shift workers, as compared to daytime workers (Zhu 
et al., 2011). Many of these differentially methylated CpG sites were located near the 
promoter sequences of circadian-related and cancer-relevant genes. Specifically, aberrant 
methylation of the circadian genes CLOCK and Cry2 was reported, with shift workers 
exhibiting CLOCK hypomethylation and Cry2 hypermethylation when compared to day 
workers, a pattern that has been associated with BC and discussed previously (Hoffman 
et al., 2010a; Hoffman et al., 2010b). In another study, a total of 50 CpG sites across 26 
unique imprinted genes showed significant differences in methylation between shift 
workers and day workers, with a tendency towards more hypomethylation than 
hypermethylation (Jacobs et al., 2013). The genes that showed the highest variation in 
methylation, distal-less homeobox 5 (DLX5) and tumour protein 73 (TP73), are genes 
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that are both linked to cancer development (Jacobs et al., 2013). The DLX5 gene is a 
transcriptional factor that promotes cell proliferation through up-regulation of c-MYC 
promoter activity and its expression has been linked with breast cancer, while the TP73 
gene is an important component of the p53 family of cell-cycle regulatory proteins and is 
altered in the majority of cancers (Morini et al., 2010; Sigal and Rotter, 2000). Together, 
these two studies were among the first to illustrate that shift work can result in aberrant 
changes to DNA methylation at specific genes that are not only linked to circadian 
rhythms, but also breast cancer development.  
  The most recent human blood-analysis study conducted a genome-wide CpG 
island methylation assay of blood samples at miRNA promoters (Shi et al., 2013). The 
results illustrated that 50 CpG loci, corresponding to 31 miRNAs, were differentially 
methylated in shift workers when compared to day workers. Among the differentially 
methylated genes was hypermethylation of the promoter for miR-219, a miRNA that has 
been linked to breast cancer development and has been identified as a potential regulator 
of circadian duration via the modulation of CLOCK- and BMAL1-dependent Per 
transcription (Cheng et al., 2007; Liu and Wang, 2012; Shi et al., 2013). To investigate 
further, the experimenters performed a genome-wide microarray on an overexpressed 
miR-219, MCF-7 breast cancer cell line, which identified 319 differentially expressed 
transcripts (Shi et al., 2013). Among the cancer-relevant pathways affected by these 
changes were increased apoptosis and immunomediated antitumour activity. In a follow-
up study, the experimenters investigated the role of another miRNA that showed 
significant promoter hypermethylation in the shift worker blood samples, miR-34b (Liu 
et al., 2015). MCF-7 breast cancer cells were transfected with miR-34b, and 230 
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differentially expressed transcripts were identified, corresponding again to increased 
apoptosis and immunomediated anti-tumour activity. Even though these studies analyzed 
DNA methylation levels at specific locations like the previous experiments discussed, 
they were the first to illustrate that the epigenetic modifications involved in CD-induced 
breast cancer may extend into miRNA regulation. 
FUTURE DIRECTIONS AND CONCLUSIONS 
  Although these handful of studies have provided valuable insights into the role of 
epigenetics in CD-induced breast cancer, there are glaring omissions and new directions 
that need to be investigated. First, none of the studies investigated the effect of CD on 
breast cancer development in mammary tissues. Second, although the experiment 
performed by Schwimmer et al. did incorporate a circadian disruption scheme on a rodent 
model, the CD scheme was not very in-depth because it did not incorporate varying 
degrees of CD, and the effect of CD was skewed due to artificial MLT levels. Third, all 
the studies focused on DNA methylation profiles, and although the Shi et al. study 
identified aberrant DNA methylation at miRNA promoters, it did not measure direct 
changes in small RNA expression due to CD. Fourth, none of the studies considered the 
potential fluctuations in epigenetic modifications due to varying time points within a 
circadian cycle. Finally, although the studies illustrated epigenetic changes due to CD and 
their potential role in breast cancer development, none of the studies showed direct 
downstream consequences due to these epigenetic modifications. Therefore, to shed new 
light on the epigenetic modifications involved in CD-induced breast cancer, focus needs 
to be placed on investigating direct CD-induced changes in DNA methylation and 
miRNA levels in mammary tissues. To accomplish this, environmentally controlled 
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experiments utilizing model systems and incorporating varying degrees of circadian 
disruption, mammary tissue extractions at various time points following CD, and 
mammary tissue extractions at specific time points within the circadian cycle, need to be 
performed. This approach will allow for a closer investigation into the dynamic and 
influence of CD on breast cancer development, and new insights and directions may be 
generated that will lead to a deeper understanding of the potential carcinogenicity of 
varying degrees of CD, influence of epigenetic circadian fluctuations on tumourigenesis, 
and the direct effect of CD on epigenetic processes in mammary tissues.  
In summary, several conclusions can be drawn from the existing literature: 
  • Circadian rhythms play a role in breast cancer development. Aberrant exposure 
to light during the dark phase of the circadian cycle can disrupt the activity of the SCN 
and cause aberrant changes to downstream processes that influence breast cancer. Among 
these processes are nocturnal MLT and core clock gene activity, with lower nocturnal 
MLT levels causing oncogenic effects and the core clock genes influencing a variety of 
cellular processes related to breast cancer. 
  • The role of epigenetics has been recognized increasingly in the etiology of 
breast cancer. Two epigenetic mechanisms, DNA methylation and miRNA activity, 
influence a variety of cellular processes related to breast cancer development. In addition, 
these two epigenetic processes have also been linked to circadian rhythms. DNA 
methylation has been shown to regulate core clock gene expression and may also 
potentially play a direct role in the circadian clock. While miRNAs have been shown to 
oscillate with the circadian cycle and directly influence components of the circadian 
clock. 
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  • Although literature has provided evidence for a link between epigenetic 
modifications and circadian rhythms, with a clear overlap existing between these two 
processes and breast cancer development, only a handful of studies have incorporated all 
three factors and directly studied the epigenetic modifications involved in CD-induced 
breast cancer. Although these studies represent a good start, there are still many aspects 
and different directions that need to be addressed when investigating the epigenetic 
modifications involved in CD-induced breast cancer.   
PRESENT STUDY AND HYPOTHESES 
  In order to address the discussed shortcomings and provide new insights on the 
epigenetic link in CD-induced breast cancer, the current study employed an 
environmentally controlled experiment using a rodent model system. To induce circadian 
disruption, a previously used photoperiod-shifting paradigm that has shown evidence of 
causing physiological and behavioural changes in rodents was utilized (Craig and 
McDonald, 2008; Devan et al., 2001). To shed new light on CD-induced BC, the study 
incorporated varying degrees of circadian disruption, mammary tissue extractions at 
various time points following CD, mammary tissue extractions at specific time points 
within the circadian cycle, analysis of gene expression and small RNA levels in the 
mammary tissues, and investigation into the potential consequences of the aberrant 
modifications identified. 
  Given evidence from previous literature, the prediction was that circadian 
disruption would result in differences between the CD-exposed and control mammary 
gland tissues in terms of gene expression and miRNA expression. More specifically, 
there would be differences in the aberrant changes based on the degree of CD, with the 
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most adamant changes occurring in the groups undergoing the highest degree of CD.  
  In terms of miRNA expression, the hypothesis was that circadian disruption 
would result in aberrant changes to miRNAs that have been shown to oscillate with the 
circadian cycle, miRNAs that target circadian-related genes, and miRNAs that are linked 
to breast cancer development. There also may be expression patterns linked to these 
miRNAs that depend on either the degree of CD or the time of tissue extraction relative 
to the circadian cycle.  
  In terms of gene expression, the hypothesis was that circadian disruption would 
result in changes to genes involved in circadian rhythms and breast cancer development, 
and that the aberrant changes would be at a high enough level to influence breast cancer 
related pathways.  
  Finally, we hypothesized that the CD-induced changes in miRNA expression 
would result in downstream consequences in the mammary tissues through changes in 
related protein levels.  
  To test these hypotheses, the study was broken down into two parts: miRNA 
expression and gene expression. Chapter 2 discusses with the miRNA results, while 
chapter 3 discusses with the gene expression results.
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Figure 1.1: Overview of the two interlocking circadian clock regulatory feedback loops. 
The blue arrows represent the BMAL1/CLOCK regulatory feedback loop which controls 
the expression of the Per and Cry genes. The orange arrows represent the regulatory 
feedback loop that controls the expression of the Bmal1 gene and formation of the 
BMAL1/CLOCK heterodimer.  
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CHAPTER 2: CIRCADIAN DISRUPTION-INDUCED MICRORNAOME 
DEREGULATION IN RAT MAMMARY TISSUES 
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O. Circadian disruption-induced microRNAome deregulation in rat mammary tissues. 
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ABSTRACT 
  Breast cancer is already the most common malignancy affecting women 
worldwide, and evidence is mounting that circadian-disruption-induced breast cancer is a 
warranted concern. Although studies on the role of epigenetics have provided valuable 
insights, and although epigenetics has been increasingly recognized in the etiology of 
breast cancer, relatively few studies have investigated the epigenetic link between 
circadian disruption (CD) and breast cancer. Using a proven photoperiod-shifting 
paradigm, differing degrees of CD, various tissue-extraction time points, and Illumina 
sequencing, we investigated the effect of CD on miRNA expression in the mammary 
tissues of a rodent model system. To our knowledge, our results are the first to illustrate 
CD-induced changes in miRNA expressions in mammary tissues. Furthermore, it is likely 
that these miRNA expression changes exhibit varying time frames of plasticity linked to 
both the degree of CD and length of reentrainment, and that the expression changes are 
influenced by the light and dark phases of the 24-hour circadian cycle. Of the 
differentially expressed miRNAs identified in the present study, all but one have been 
linked to breast cancer, and many have predicted circadian-relevant targets that play a 
role in breast cancer development. Based on the analysis of protein levels in the same 
tissues, we also propose that the initiation and development of CD-induced breast cancer 
may be linked to an interconnected web of increased NF-κB activity and increased levels 
of Tudor-SN, STAT3, and BCL6, with aberrant CD-induced downregulation of miR-127 
and miR-146b potentially contributing to this dynamic. This study provides direct 
evidence that CD induces changes in miRNA levels in mammary tissues with potentially 
malignant consequences, thus indicating that the role of miRNAs in CD-induced breast 
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cancer should not be dismissed.      
 INTRODUCTION 
  In 2007, the International Agency for Research on Cancer concluded “shiftwork 
that involves circadian disruption is probably carcinogenic to humans” (Hansen and 
Stevens, 2012). Studies conducted before and since this claim have all contributed 
evidence that breast cancer induced by circadian disruption (CD) is a warranted concern. 
Amongst the supporting evidence are aberrant, nocturnal melatonin levels contributing to 
breast cancer development, a role of circadian-relevant genes in breast cancer, and case 
study findings showing indirect evidence that night-shift workers are at higher risk of 
developing breast cancer (Blask et al., 2003; Cos et al., 2006; Hansen and Stevens, 2012; 
Haus and Smolensky, 2013; Knutsson et al., 2013). Although many studies have been 
conducted on the potential mechanisms in CD-induced breast cancer, very few of these 
studies have investigated the epigenetic links that may be involved. One of these potential 
epigenetic links is the activity of microRNAs (miRNAs), and the role of these small 
RNAs in both circadian rhythms and the etiology of breast cancer have been increasingly 
recognized (Jovanovic et al., 2010; Koturbash et al., 2011; Pegoraro and Tauber, 2008).   
  Mature miRNAs are abundant, small, single-stranded noncoding RNAs that are 
potent regulators of gene expression (Hwang and Mendell, 2006). Approximately 22 nts 
long, mature miRNAs associate with the RNA induced silencing complex (RISC) and 
target the 3` UTR region of target mRNAs, resulting in gene degradation or suppression, 
depending on the level of complementarity between the miRNA and its target (Koturbash 
et al., 2011). In mammals, through this mechanism a single miRNA can target multiple 
genes and influence a broad range of cellular processes related to cancer (Koturbash et 
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al., 2011). Acting as tumour suppressors, tumour promoters referred to as oncomiRs, or 
both depending on the degree of malignancy, miRNAs can influence the progression of 
cancer through various mechanisms such as cellular differentiation, proliferation, and 
apoptosis (Jovanovic et al., 2010; Koturbash et al., 2011).  
 In addition to playing a role in breast cancer development, miRNAs have also 
been shown to oscillate with the circadian cycle and target circadian-relevant genes. In 
Arabidopsis, several miRNAs were shown to oscillate based on environmental light, 
exhibiting higher levels during the daytime than during the nighttime, and oscillation on 
the basis of photic control and not an internal clock (Sire et al., 2009). In a study 
conducted on HeLa cell lines, results showed that the miR-192/194 cluster directly 
regulates the entire Period gene family, with increased expression of the miR192/194 
tandem causing lowered expression of the Period genes and a shortening of the circadian 
cycle (Nagel et al., 2009). Further investigation has illustrated that miR-132 expression is 
induced by light within the suprachiasmatic nucleus (SCN) and that it has the capacity to 
restore homeostasis and reset the activity caused to the circadian clock by nocturnal light 
(Alvarez-Saavedra et al., 2011). Interestingly, a recent study has also reported that miR-
132 levels are lowered in breast cancer cells, and identified miR-132 as a tumour 
suppressor that acts by inhibiting proliferation, migration, invasion, and metastasis 
(Zhang et al., 2014).  
  Despite the increasing evidence that miRNAs play a role in breast cancer 
development and in circadian rhythms and that these roles likely overlap, information on 
the involvement of miRNAs in CD-induced breast cancer remains scarce. In the handful 
of studies that have investigated epigenetic modifications in CD-induced breast cancer, 
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all the experiments have focused on changes in DNA methylation (Jacobs et al., 2013; 
Schwimmer et al., 2014; Zhu et al., 2011). Although the most recent study of epigenetic 
CD-induced breast cancer conducted a DNA methylation analysis on shift worker blood 
samples at miRNA promoters and identified increased methylation of breast cancer 
relevant miRNAs, the study did not measure expression levels of miRNAs or investigate 
CD-induced changes in mammary tissues (Liu et al., 2015; Shi et al., 2013). Furthermore, 
although the DNA methylation studies mentioned have provided valuable insights into 
the epigenetic role in CD-induced breast cancer, none of them have investigated the 
effect of varying degrees of CD or the influence of fluctuations within a 24-hour 
circadian cycle. Therefore, to shed new light on the epigenetic mechanisms involved in 
CD-induced breast cancer, the current study utilized a photoperiod-shifting (PS) 
paradigm involving various degrees of CD and specific time points within a circadian 
cycle to investigate the influence of CD on miRNA expression in the mammary tissues of 
a rodent model system.  
MATERIALS AND METHODS 
Animal model and circadian-disruption paradigm 
  Female Sprague Dawley rats from Charles River (Quebec) were housed at the 
Canadian Center for Behavioural Neuroscience at the University of Lethbridge. The rats 
were housed in a sterile facility in a temperature-controlled room, two per cage, and 
given food and water ad libitum. Handling and care of the animals was performed in 
accordance with the recommendations of the Canadian Council on Animal Care, and 
procedures were approved by the University of Lethbridge Animal Welfare Committee. 
Before the start of the experiment, all the rats were entrained to a 12-hour light-dark cycle 
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for 22 days to allow entrainment to a normal light schedule. At 83 days old, the rats were 
then randomly assigned to different treatment and control groups. 
  CD was induced by following a photoperiod-shifting paradigm that has been 
shown to cause physiological and behavioural changes in rodents (Craig and McDonald, 
2008; Deibel et al., 2014; Devan et al., 2001; McDonald et al., 2013). In total, 40 female 
rats underwent this PS paradigm. To stimulate PS, the colony lights were turned on three 
hours earlier on each successive day of the experiment (Supplementary Tables S1 and 
S2). To investigate the effect of varying degrees of CD, the 40 rats were separated into 
acute and chronic CD groups. Twenty rats underwent acute photoperiod shifting, which 
consisted of lights coming on three hours earlier each day for a total cycle time of six 
days (Supplementary Table S1). Another 20 rats underwent chronic photoperiod shifting, 
which consisted of a rotation between a six-day period in which lights came on three 
hours earlier each day and a 10 day period in which a regular 12-hour light-dark cycle 
was followed, for a total cycle time of 54 days (Supplementary Table S2). For both the 
acute (six days) and chronic groups (54 days), following the PS cycle, the rats were 
exposed to a normal 12-hour light-dark cycle until it was time for tissue extraction.   
  The acute (20 rats) and chronic (20 rats) CD groups were then separated further 
based on the time of tissue extraction (Supplementary Figure S1). Mammary tissue 
extractions occurred 24 hours and two weeks following acute or chronic CD, with 10 rats 
from each CD group undergoing tissue extraction at each of these times. To account for 
and investigate the potential influence of specific time points within a 24-hour circadian, 
two different tissue-extraction time points, each corresponding to a specific zeitgeber 
time (ZT), were chosen for each tissue-extraction day (24 hours and two weeks following 
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CD). Half of the rats (five) in each tissue-extraction group were sacrificed at ZT06 (six 
hours after lights on), and the remaining five rats in each group were sacrificed at ZT19 
(19 hours after lights on). These two ZT points were chosen because they represented the 
light and dark phases of the circadian cycle. 
  Both the acute (20 rats) and chronic (20) control groups were exposed to a 12-
hour light-dark cycle for either six days (acute) or 54 days (chronic). The rats from each 
CD control group were then exposed to a 12-hour light-dark cycle for either 24 hours (10 
rats) or two weeks (10 rats), depending on the time of tissue extraction for the 
corresponding experimental group. From each tissue-extraction control group (10 rats), 
five rats were sacrificed at ZT06 and five rats at ZT19 on the corresponding tissue-
extraction day.  
  Euthanasia of the rats was performed through anaesthesia with Isoflurane (4‒5 %; 
oxygen at 2 litres per minute) and decapitation by a guillotine, with euthanasia of the rats 
alternating between the control and experimental rats. The mammary glands were 
collected, immediately stored in liquid nitrogen, and stored long-term at -80°C.  
Total RNA extraction 
  Whole mammary tissues were ground in liquid nitrogen using sterile, chilled 
mortars and pestles. Approximately 0.05 g of ground tissue from each sample was then 
suspended in Zymo Research tri-reagent (R2053) and lysed using two cycles of the 
Qiagen Tissue Lyser II for 2 minutes at 25 Hz. Total RNA was then extracted using the 
direct-zol RNA Miniprep kit from Zymo Research (R2053). The quality of the RNA was 
checked using NanoDrop 2000c, and quality bioanalysis was conducted using the Agilent 
2100 and the Agilent Small RNA Kit and Chip (5067-1548); only samples with an RNA 
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integrity value (RIN) greater than 8 were used in downstream applications.  
Small RNA sequencing and bioinformatics analysis 
  Three samples from each tissue-extraction and ZT group for both the 
experimental and control groups were randomly chosen to undergo sequencing analysis. 
The TruSeq Small RNA Sample Preparation Kit for 25‒36 indexes from Illumina (RS-
200-0036) was used to prepare small RNA libraries from 1 µg of total RNA. Six-percent 
SDS-PAGE gels were run to cut out the bands of interest for library validation on the 
Agilent 2100 using the Agilent High Sensitivity DNA Kit and Chip (5067-4626). Cluster 
generation for sequencing was performed using cBot and the TruSeq SR Cluster Kit v2-
cBot-GA (GD-300-2001) from Illumina. Single-end sequencing was performed using the 
TruSeq SBS Kit v5-GA (FC-104-5001) from Illumina on the Genome Analyzer GAIIx at 
36 cycles. 
   Bioinformatics analysis was performed on the sequencing data to define 
expression levels of miRNAs amongst the different experimental groups. Quality of the 
libraries was evaluated using FastQC v0.10.1 software. Adapter trimming was done using 
Cutadapt (https://code.google.com/p/cutadapt/). Trimmed reads were converted to fasta 
using an ad-hoc perl script and collapsed to unique tags with the fastx_collapser program 
from the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Unique tags in fasta 
format were aligned to mature miRNA sequences downloaded from miRBase (release 
19) using Micro-Razers; only unambiguous alignments were kept (Emde et al., 2010). An 
ad hoc perl script was used to process the MicroRazers alignment file to produce a tab 
delimited count file containing miRNA IDs and raw read count columns.  
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Small RNA qRT-PCR 
  Validation of the sequencing results was performed by qRT-PCR. Small RNA 
cDNA was synthesized from 150ng of RNA using the reagents and protocol associated 
with the GeneCopoeia All-in-One miRNA First-Strand cDNA Synthesis Kit (AMRT-
0060). The small RNA qPCRs were performed utilizing SYBR Green on the BioRad 
C1000 Thermal Cycler and CFX96 Real-Time System, by using the reagents and 
protocol associated with the GeneCopoeia All-in-One miRNA qRT-PCR detection kit 
(AOMD-Q060). All reactions were run in triplicate, and the program used was the one 
recommended by GeneCopoeia (10 min at 95°C; 40 cycles of 10 sec at 95°C, 20 sec at 
60°C, and 10 sec at 72°C). Efficiency standard curves for the primers were generated 
using serial dilutions, and following all the qPCR cycling, melt curve analysis was 
conducted using the optimal parameters for the BioRad C1000 thermal cycler (65°C to 
95°C, increments of 0.5°C).  
  The reverse primer used for all the reactions was the Universal Adaptor Primer 
included in the miRNA qRT-PCR detection kit from GeneCopoeia (AOMD-Q060). All 
the forward primers were miRNA-specific primers ordered from GeneCopoeia based on 
the target of interest, for example, rno-miR-127-3p (RmiRQP0111). Based on previous 
publications, recommended endogenous reference genes were ordered from GeneCopoeia 
and tested for stability (Davoren et al., 2008; Wang et al., 2013). The best combination of 
two reference genes, rno-miR-16 (RmiRQP0227) and rno-let-7a (RmiRQP0002), was 
found using the programs NormFinder (http://moma.dk/normfinder-software) and 
qbaseplus (Biogazelle), with the stability values meeting the geNorm stability cutoffs (CV 
< 0.25, M-Value < 0.5). These two reference genes have been recommended as control 
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genes for miRNA expression analysis in breast cancer (Davoren et al., 2008). 
Western blot analyses 
  A 0.07 g portion of each mammary tissue sample was lysed and sonicated in 350 
µl of 1%SDS+ProteaseInhibitor. Next, the samples were placed in a 95ºC water bath for 
5 minutes and then centrifuged at 10,000 g for 10 minutes at 4ºC. The supernatant was 
collected and centrifuged at 10,000g for 10 minutes at 4ºC. Protein content was 
determined with the Bradford protein determination assay from BioRad. Equal amounts 
of lysate protein (10 µg/10 µL) were run on 6‒10% SDS-polyacrylamide gels and 
transferred to PVDF membranes from GE Healthcare.  
  Western immunoblotting was conducted following well established protocols 
(Kovalchuk et al., 2008). Unaltered PVDF membranes were stained with Coomassie Blue 
(BioRad) to ensure even blotting of the proteins. Membranes were incubated with various 
primary antibodies at different dilutions based on the antibody company, antibodies 
against rabbit anti-BCL6 (1:1000, Abcam), mouse anti-Tudor-SN (1:500, Santa Cruz), 
rabbit anti-STAT3 (1:500, Santa Cruz), rabbit anti-phospho-NFκB p65 (Ser311) (1:500, 
Santa Cruz), rabbit anti-DNMT1 (1:500, Santa Cruz), and mouse anti-βactin (1:1000, 
Abcam). Antibody binding was revealed by incubation with horseradish peroxidase-
conjugated secondary antibodies based on the primary antibody source animal (Santa 
Cruz) and the ECL Plus immunoblotting detection system (GE Healthcare). 
Chemiluminescence was detected using the FluorChem HD2 from Cell Biosciences. 
Signals were quantified using NIH ImageJ software and normalized to the actin protein 
band.  
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Statistical analyses 
  For statistical analyses of the bioinformatics data, raw count files were loaded into 
R version 3.1.2. All the statistical comparisons were performed using the DESeq2 
(version 1.4.5) bioconductor package as described in the package manual (Anders and 
Huber, 2010). Multiple comparisons adjustment was performed using Benjamini-
Hochberg procedure, and microRNAs with an adjusted p-value below 0.1 were 
considered differentially expressed (Benjamini and Hochberg, 1995). Sample and 
miRNA clustering based on Euclidian distances was performed using the gplots R 
package, and the clustering results were displayed graphically as MA plots and heatmap 
dendrograms. For the qRT-PCR and western blot data, Student’s t-test was used for 
independent variance to determine significance (p < 0.05). Statistical analysis and 
plotting of the data was performed using MS Excel software for Windows, and the results 
were presented as mean relative expression values ± standard error of the mean (SEM). 
RESULTS 
Circadian disruption causes aberrant expression of a broad range of miRNAs, and 
the changes are linked to an early time point in the circadian cycle 
  In this study, we investigated the effect of varying degrees of CD on miRNA 
expression in the mammary tissues of Sprague Dawley rats. The influence of light-
dependent zeitgeber times was also incorporated to investigate possible fluctuations 
within a 24-hour circadian cycle. The sequencing results identified a broad range of 
miRNAs that were differentially expressed between the circadian-disrupted samples and 
the control samples (Table 2.1). Amongst the differentially expressed miRNAs, all but 
one play a role in breast cancer development (Table 2.1). Numerous miRNAs that 
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oscillate with the circadian cycle and/or have predicted circadian-relevant targets were 
also differentially expressed due to circadian disruption (Table 2.1).  
  The changes in miRNA expression were observed in both the acute and chronic 
circadian-disrupted groups, as well as in both the 24-hour and two-week tissue-extraction 
groups (Figures 2.1‒2.3). Only the two-week acute group did not show any changes in 
miRNA expression (Figures 2.3 and 2.4). Interestingly, the time of tissue extraction based 
on ZT influenced the results. None of the ZT19 groups showed any changes in miRNA 
expression (Figure 2.4), whereas with the exception of the two-week acute group, all the 
ZT06 groups showed differences in miRNA expression compared to the respective 
control groups (Figures 2.2 and 2.3). The ZT19 and ZT06 extraction time points 
represented the dark and light phases of the circadian cycle, respectively, indicating that 
the miRNA expressions correlated to light-dependent time points within the circadian 
cycle. 
 Between the ZT06 groups that showed differences in miRNAs, there were no 
significant correlations or patterns in specific miRNA expression, with only two miRNAs 
being differentially expressed in more than one group, miR-150-5p and miR-142-5p 
(Table 2.2). Furthermore, with the exception of no differential expression in the two-
week acute ZT06 group, there was no significant difference in the number of 
differentially expressed miRNAs based on the degree of CD (Table 2.2).  
 In terms of expression patterns within each individual ZT06 group, the 24-hour 
acute group had a tandem cluster that was differentially expressed, with downregulation 
of the tumour suppressor miRNAs, miR-1 and miR-133a (Tables 2.1 and 2.2). Within the 
24-hour chronic ZT06 group, two miRNAs from the same gene family that are linked to 
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breast cancer and circadian rhythms, let-7b and let-7c, were differentially expressed 
(Tables 2.1 and 2.2). Finally, in the two-week chronic ZT06 group, both miR-146a and 
miR-146b, which belong to the same gene family, were downregulated (Tables 2.1 and 
2.2).  
Validation of sequencing results through qRT-PCR verifies miR-127 expression 
  Of the three ZT06 groups that illustrated differential expression of miRNAs due 
to CD, emphasis was placed on the two-week chronic ZT06 group due to the differential 
expression of miRs 146a and 146b, and miR-127 (Figures 2.5A-B and 2.6A). 
Confirmation of the two-week chronic ZT06 miRNA sequencing results was attempted 
through small RNA qRT-PCRs. However, the biggest log fold change in miRNA 
expression based on Illumina sequencing in this group was approximately 1 (Figure 2.2). 
This made verification of the sequencing results difficult, both because of the sensitivity 
of qRT-PCR and the fact that qPCR is not an infallible validation method, especially 
when the technology being validated incorporates PCR-based amplification, as does 
Illumina (Git et al., 2010). Amongst the qRT-PCRs performed on the differentially 
expressed miRNAs in the two-week chronic ZT06 group, the miR-127 qPCR results 
validated the sequencing results. The qPCR data illustrated a similar and consistent 
change in relative miR-127 expression when compared to the Illumina sequencing 
(Figures 2.6A and 2.6B).  
Circadian-disruption-induced changes in miRNA expression in the two-week 
chronic ZT06 group correlated to aberrant levels of breast-cancer-relevant proteins 
  To investigate the potential downstream consequences of changes in miRNA 
expression due to CD in the two-week chronic ZT06 group, western blot analysis was 
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performed on relevant proteins linked to the differentially expressed miRNAs and breast 
cancer development. With respect to miR-146a and 146b activity, the results illustrated 
higher quantities of the transcriptionally active form of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) (Figure 2.5). Phospho-NFκB (p65) protein levels 
showed a nearly 2.5-fold increase in the circadian-disrupted samples compared to the 
control samples, and a p-value of less than 0.05 (Figure 2.5D). The results also illustrated 
higher quantities of a verified target of miR-127 and a protein linked to cellular 
senescence, B-cell lymphoma 6 (BCL6) (Figure 2.6). BCL6 protein levels showed a 
twofold increase in the circadian-disrupted samples, and a p-value of less than 0.05 
(Figure 2.6D). Western blot analysis also showed higher quantities of tudor 
staphylococcal nuclease (Tudor-SN), a protein liked to NF-kappaB activity and lower 
miR-127 expression (Figure 2.6). Tudor-SN protein levels showed an almost threefold 
increase in the circadian-disrupted samples compared to the control samples and a p-
value of less than 0.01 (Figure 2.6D). Western blot analysis was also conducted on signal 
transducer and activator of transcription 3 (STAT3) (Figure 2.7). The data showed that 
STAT3 protein levels had a 0.5-fold increase in the circadian disrupted samples 
compared to the control samples, and a p-value of less than 0.05 (Figure 2.7B). Increased 
STAT3 levels are linked to lower expression of miR-146b and increased NF-κB activity, 
both of which were present in the two-week chronic ZT06 group (Figure 2.5). To 
investigate whether DNA methylation differences may have contributed to the aberrant 
expression of the differentially expressed miRNAs, western blot analysis was conducted 
on the maintenance DNA methyltransferase, DNMT1 (Figure 2.8). The results showed 
that DNMT1 protein levels increased more than twofold in the circadian-disrupted 
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samples compared to the control samples, with a p-value of less than 0.05 (Figure 2.8B). 
DISCUSSION 
  Knowledge on the influence of varying degrees of CD and miRNA activity in 
CD-induced breast cancer remains scarce. Our study, which induced CD using a 
photoperiod-shifting paradigm shown to cause behavioural and physiological changes in 
rodents, is to our knowledge the first to illustrate that CD induces changes in miRNA 
expression in rodent mammary tissues (Craig and McDonald, 2008; Deibel et al., 2014; 
Devan et al., 2001; McDonald et al., 2013). Both the acute and chronic CD manipulations 
resulted in the differential expression of a variety of breast-cancer-relevant and 
potentially circadian-relevant miRNAs (Table 2.1 and Figure 2.1). The 54 day chronic 
CD scheme caused changes in miRNA expression in both the 24-hour and two-week 
chronic extraction groups (Figure 2.2), indicating that long-term CD can have aberrant 
consequences on breast cancer development through miRNA activity. Because the 6 day 
acute CD scheme also caused aberrant changes in miRNA expression in the 24-hour 
group (Figure 2.3), this suggests that even short-term CD may induce potentially harmful 
changes that can increase the risk of circadian-related diseases.  
  Amongst the experimental groups in the study, only the two-week acute group did 
not show any significant changes in miRNA expression (Figures 2.3 and 2.4). The two-
week acute group underwent the least rigorous CD-scheme and had the longest 
reentrainment period before tissue extraction. This information, coupled with the fact that 
the 24-hour acute and two-week chronic groups did exhibit changes in miRNA 
expression (Figure 2.1), indicates that the CD-induced changes in miRNA levels may be 
linked to the degree of CD and a correlated length of reentrainment to restore normal 
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miRNA expression. These results are supported by evidence from previous studies 
indicating that CD effects on various processes can be plastic. By utilizing the same acute 
photoperiod-shifting paradigm used in the present study, a study used behavioural 
measurements to show that rats required 17 days of a 12-12 light-dark cycle to attain 
reentrainment (Devan et al., 2001). In terms of epigenetic modifications, a study 
illustrated that CD-induced changes in DNA methylation can be reversed, showing that 
circadian disrupted mice that are entrained back to a regular 24-hour day exhibit a 
reversion in DNA methylation levels (Azzi et al., 2014). Based on our results, it would 
seem that 14 days or fewer on a 12-12 light-dark cycle is enough time to cause a 
reversion in miRNA levels due to the acute CD scheme used, but not enough time to 
cause reversion due to the chronic CD scheme. Along with evidence from previous 
literature, this indicates that CD-induced miRNA changes are likely plastic, with varying 
degrees of CD requiring varying lengths of reentrainment to revert the changes in 
miRNA expression.  
  Through the incorporation of light-dependent ZT extractions, our results also 
illustrate that specific time points within a circadian cycle may play an important role in 
miRNA activity and CD-induced breast cancer. Specifically, the results showed that none 
of the groups representing the dark phase of the circadian cycle, the ZT19 extraction 
groups, exhibited any changes in miRNA expression (Figure 2.4). In terms of the ZT06 
groups, which represent the light phase of the circadian cycle, all but the two-week acute 
group showed differences in miRNA levels (Figures 2.2 and 2.3). Previous literature has 
demonstrated that miRNAs can oscillate throughout a 24-hour circadian cycle. In 
particular, a microarray-based experiment on mouse liver revealed that over 13% of the 
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probed miRNAs exhibited circadian expression patterns (Na et al., 2009). Interestingly, 
some of the miRNAs identified in that study are miRNAs that exhibited differential 
expression in our study (Table 2.1). Therefore, our findings further stress that specific 
time points within a 24-hour circadian cycle are important for accurately measuring 
miRNA levels and activity, and that these details need to be considered when 
investigating circadian-relevant diseases. For example, melatonin, a pineal hormone that 
is linked to circadian rhythms and exhibits fluctuations in its daytime and nocturnal 
concentrations, has been shown to influence human breast cancer xenografts through a 
day-night rhythm of tumour proliferation, fatty acid uptake, metabolism, and signal 
transduction activity (Blask, 2009; Reiter, 2004). Research has also reported that DNA 
methylation activity may be influenced by light-dependent induction or repression of 
DNA methylation enzymes (Azzi et al., 2014). Therefore, given these previous findings, 
coupled with the fact that miRNAs can influence cancer-relevant processes and also 
fluctuate with the circadian cycle, it is not inconceivable that circadian-dependent 
fluctuations in miRNAs can influence breast cancer development. Our results illustrate a 
clear pattern of CD-induced changes in miRNA expression based on the light and dark 
phases of the circadian cycle (Figures 2.2 and 2.4), and all but one of the differentially 
expressed miRNAs are linked to breast cancer development (Table 2.1). It is therefore 
likely that circadian fluctuations in miRNA activity are an important component in the 
development of CD-induced breast cancer and should not be ignored.  
  In terms of specific miRNAs that were differentially expressed due to CD, all but 
one have been linked to breast cancer development, with many of the CD-induced 
expressions correlating to potentially aberrant consequences (Tables 2.1 and 2.2). 
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Although only two miRNAs were identified in more than one of the ZT06 groups, miR-
142-5p and miR150-5p (Table 2.2), there are significant correlations and patterns related 
to breast cancer development in each ZT06 group. In the 24-hour acute ZT06 group, two 
miRNAs that are part of the same cluster, miR-133a and miR-1, were both 
underexpressed (Table 2.2). The miR-1/133a cluster has been shown to be downregulated 
in a variety of cancers, whereas miRNA-133a has also been shown to act as a tumour 
suppressor in breast cancer cells by causing S/G2 phase cell-cycle arrest through activity 
on phosphorylated protein kinase B (Akt) (Cui et al., 2013; Nohata et al., 2012). 
Furthermore, two predicted circadian-relevant targets of the miR 1/133a cluster are 
circadian locomotor output cycles kaput (CLOCK) and TIMELESS (Table 2.1). Previous 
literature has shown that CLOCK knockdown in breast cancer cells results in increased 
expression of various tumour suppressor genes and decreased expression of multiple 
oncogenes, indicating an oncogenic influence by CLOCK that is potentially an early 
event in breast cancer development (Hoffman et al., 2010a). TIMELESS, a circadian and 
cell-cycle regulator that may act as a molecular bridge between these two regulatory 
systems, has been reported to be overexpressed in many breast cancer cells, with the 
increased expression being linked to increased proliferation and poorer prognostic 
outcome (Fu et al., 2012; Mao et al., 2013). This indicates that CD-induced down 
regulation of the miR-1/133a cluster may have oncogenic effects through previously 
identified mechanisms, as well as through potential circadian relevant targets.   
  In the two-week chronic ZT06 group, two miRNAs from the same gene family, 
miR-146a and 146b, were downregulated (Table 2.2). The expression of miR-146a and 
146b has been shown to suppress NF-κB activity (Bhaumik et al., 2008; Walker et al., 
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2014). A key component of inflammation and innate immunity, NF-κB is a protein 
complex that controls the transcription of numerous genes and has been implicated as a 
key component in many steps of cancer initiation and progression (Helbig et al., 2003; 
Hoesel and Schmid, 2013; Shostak and Chariot, 2011). Activation of NF-κB can result in 
the upregulation of anti-apoptotic genes and contribution to cell survival and proliferation 
(Hoesel and Schmid, 2013). In breast cancer, NF-kappaB has been shown to increase cell 
migration and promote tumour-initiating cells (Helbig et al., 2003; Kendellen et al., 
2014). Our western blot results show that activated NF-κB was significantly increased in 
the circadian-disrupted samples of the two-week chronic ZT06 group (Figure 2.5C-D). 
This finding is consistent with a previous study that indirectly correlated increased 
induction of NF-κB pathways to CD-induced promoter methylation of miR-219 (Shi et 
al., 2013). The present study shows that CD results in a direct increase of NF-κB activity 
in mammary tissues and that this activity may be linked to CD-induced downregulation 
of miR-146a and 146b (Figure 2.5).    
  Cellular senescence is a response to extracellular and intracellular stresses, such 
as oncogenic stimuli, that causes permanent cell-cycle arrest and acts as a potent tumour 
suppression mechanism that prevents the oncogenic transformation of primary cells 
(Campisi, 2013). miRNA-127-3p has been shown to be upregulated in senescent cells, 
and its downregulation has been shown to promote cell proliferation (Pan et al., 2012; 
Wang et al., 2011). Small RNA sequencing and validation through qRT-PCR showed that 
miR-127 is underexpressed in the two-week chronic ZT06 group (Figure 2.6A-B). 
Because cell senescence plays an important role in tumour initiation, this dynamic 
warranted further investigation (Rodier and Campisi, 2011). Amongst the proteins linked 
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to miR-127 activity and breast cancer development, are BCL6 and Tudor-SN. A target of 
miR-127, the BCL6 gene has been identified as a potent inhibitor of cell senescence and a 
contributor to oncogenesis, and the western blot data showed that BCL6 levels were 
significantly increased in the circadian-disrupted samples (Figure 2.6) (Chen et al., 
2013a; Shvarts et al., 2002). Tudor-SN is a member of the RISC complex and also known 
as SND1, and it has been implicated in various cancers and has been shown to regulate 
miRNA processing and expression by degrading primary-miRNA transcripts that 
undergo adenosine deaminase acting on RNA (ADAR) editing (Blanco et al., 2011; 
Kuruma et al., 2009; Scadden, 2005; Yang et al., 2006). In terms of its link to cancer 
progression, Tudor-SN has been shown to promote resistance to apoptosis and to be 
induced by NF-κB, which as mentioned above, was increased in the CD-induced tissues 
through potentially decreased miR-146a and 146b expression (Figure 2.5) (Armengol et 
al., 2013; Blanco et al., 2011). Amongst the miRNAs influenced by Tudor-SN, is miR-
127, and studies have shown that Tudor-SN triggers miR-127 downregulation in breast 
cancer cells (Zhao et al., 2013). Our western blot results illustrate that Tudor-SN was 
significantly increased in the CD-induced tissues (Figure 2.6). This indicates that CD 
causes aberrant expression of Tudor-SN, which may be linked to increased NF-κβ 
activity through CD-induced repression of miR-146a and 146b. Consequently, this 
dynamic potentially results in the decreased expression of miR-127 through increased 
Tudor-SN activity, which in turn results in increased expression of the proto-oncogene 
BCL6. 
  Numerous publications have provided evidence that the STAT3 gene produces 
oncogenic effects in a variety of cancers, including being active in 50‒60% of primary 
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breast tumours and being linked to the promotion of breast cancer stem cell traits (Chung 
et al., 2014; Siveen et al., 2014). Our western blot data illustrate that STAT3 levels 
showed a significant increase in the CD-induced samples in the two-week chronic ZT06 
group (Figure 2.7). Interestingly, STAT3 has also been identified as part of a negative 
feedback loop with miR-146b. In healthy cells, the gene encoding miR-146b is a direct 
target of STAT3, and as STAT3 levels increase, it results in the activation of miR-146b 
(Walker et al., 2014; Xiang et al., 2014). The activation of miR-146b results in the 
attenuation of NF-κB activity, which in turn, results in the subsequent inhibition of 
STAT3 expression (Walker et al., 2014; Xiang et al., 2014). In breast cancer cells, 
increased promoter methylation of miR-146b results in inhibition of the negative 
feedback loop and increased expression of STAT3 (Xiang et al., 2014). As mentioned, 
miRNA146b levels were downregulated in the circadian-disrupted samples and NF-κB 
activity was also increased (Figure 2.5). Although no promoter-specific DNA 
methylation analysis was performed in this study, western blot data indicate that there 
were increased levels of DNMT1 in the circadian-disrupted samples (Figure 2.8). 
Together with previous literature that has shown that CD results in increased miRNA 
promoter methylation, this indicates that the aberrant NF-κB activity and STAT3 levels 
could potentially be a consequence of miR-146b promoter methylation due to increased 
levels of DNMT1 (Etoh et al., 2004; Shi et al., 2013). Furthermore, the STAT3 protein 
has also been shown to induce BCL6 expression by binding to one of two regulatory 
regions within the BCL6 gene (Walker et al., 2013). As a result, the CD-induced 
increases in STAT3 expression through NF-κB activity may not only cause oncogenic 
effects on their own, but also contribute to the increase in BCL6 levels. In view of the 
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previously discussed results, it seems that CD results in a cascade of interrelated activity 
that revolves around increased NF-κB activity and expression of BCL6, with aberrant 
CD-induced downregulation of miR-127 and miR-146b potentially contributing to this 
cascade.  
  Our findings illustrate for the first time that CD induces changes in miRNA levels 
in mammary tissues. In addition, these CD-induced changes are likely plastic and 
potentially linked to the light and dark phases of the circadian cycle. Among the 
differentially expressed miRNAs reported, are breast-cancer-relevant miRNAs that also 
have predicted circadian-relevant targets linked to breast cancer development. The basis 
of the link between miRNA activity and CD-induced breast cancer seems to be an 
interconnected web of increased NF-κB activity and BCL6 expression, likely linked to 
and promoted by the CD-induced decrease in miR-127 and miR-146b. Because 
inflammation, innate immunity, and cellular senescence are crucial in tumour initiation 
and breast cancer progression, and because these two miRNAs have been linked to these 
mechanisms, it is likely that all of them are key, interrelated components in the potential 
initiation and development of CD-induced breast cancer. Although our findings are 
bolstered by previous literature, given that they represent the first evidence of potentially 
direct consequences of aberrant CD-induced miRNA activity in mammary tissues, further 
investigation is required. A stricter CD scheme in terms of ZT extractions and extractions 
following CD is warranted for developing a more accurate range of CD-induced miRNA 
plasticity and for providing more details on the potential consequences of light-dependent 
miRNA fluctuations in CD-induced breast cancer. Verification of potential circadian-
relevant targets through luciferase reporter experiments, incorporation of the CD schemes 
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into xenograft models, and further investigation of the dynamic of miR-127 and miR-
146b activity in cancer cells are all logical extensions of the present study. In either case, 
whatever the next avenue may be, this study provides evidence that CD induces changes 
in miRNA levels in mammary tissues with potentially malignant consequences, thus 
indicating that the role of miRNAs in CD-induced breast cancer should not be dismissed.      
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Table 2.1: Circadian disruption induces changes in a broad range of breast cancer 
relevant miRNAs. Differentially expressed miRNAs based on Illumina sequencing in all 
the circadian-disrupted samples and their links to breast cancer development and 
circadian rhythms.  
miRNA Links to Breast Cancer Development 
Links to Circadian 
Rhythms 
 
let-7b-5p Tumour suppressor linked to cell motility Cry2; Circadian 
oscillation 
let-7c-5p Tumour suppressor Cry2 
miR-1-3p Tumour suppressor in various cancers, possibly linked to BC CLOCK 
miR-10a-5p Amplified in and linked to ER+ breast cancer 
 
miR-15b-5p Tumour suppressor linked to BCL2 expression 
 
miR-24-3p Enhances tumour invasion and metastasis Per2 
miR-30b-5p Linked to tumourigenesis and metastasis 
 
miR-99a-5p Tumour suppressor linked to mTOR expression Circadian oscillation 
miR-126a-5p Linked to metastasis NPAS2 
miR-127-3p Tumour suppressor linked to BCL6 expression 
 
miR-130a-3p OncomiR 
 
miR-133a-3p Tumour suppressor linked to tumour growth 
and invasion TIMELESS 
miR-142-5p Linked to ER/PR status Circadian oscillation 
miR-146a-5p Tumour suppressor linked to NFκB Circadian oscillation 
miR-146b-5p Tumour suppressor linked to STAT3 and NFκB TIMELESS; Circadian oscillation 
miR-150-5p OncomiR linked to apoptosis Circadian oscillation 
miR-193-3p Tumour suppressor Cry2 
miR-335 Linked to breast cancer development and BRCA1 CLOCK 
miR-672-5p ---------------------------------- 
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Figure 2.1: Circadian disruption causes changes in miRNA expression in both the acute 
and chronic groups. Heat map dendrograms based on the Illumina sequencing results 
for the differentially expressed miRNAs in the A. 24-hour acute ZT06 group and B. two-
week chronic ZT06 group. All the differentially expressed miRNAs represent a significant 
expression difference, p-adjusted < 0.1, N=6.  
A B 
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Figure 2.2: Chronic circadian disruption causes significant changes in miRNA 
expression in the ZT06 groups. MA plot based on the small RNA Illumina sequencing 
results for the A. 24-hour chronic ZT06 group and B. two-week chronic ZT06 group. The 
y-axis represents log fold change, while the x-axis represents mean expression. The plots 
represent all the miRNA expressions that were identified, and the red plots represent 
miRNAs that showed a significant expression difference; p-adjusted < 0.1, N=6. Each red 
plot is identified with the corresponding miRNA.   
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Figure 2.3: Acute circadian disruption causes significant changes in miRNA expression 
in the 24-hour acute ZT06 group. MA plot based on the small RNA Illumina sequencing 
results for the A. 24-hour acute ZT06 group and B. two-week acute ZT06 group. The y-
axis represents log fold change, while the x-axis represents mean expression. The plots 
represent all the miRNA expressions that were identified, and the red plots represent 
miRNAs that showed a significant expression difference; p-adjusted < 0.1, N=6. Each red 
plot is identified with the corresponding miRNA.  
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Figure 2.4: Chronic and acute circadian disruption causes no significant changes in 
miRNA expression in all the ZT19 groups.  MA plots based on the small RNA Illumina 
sequencing results for the A. 24-hour chronic ZT19 group, B. two-week chronic ZT19 
group, C. 24-hour acute ZT19 group, and D. two-week acute ZT19 group. The y-axis  
represents log fold change, while the x-axis represents mean expression. The plots 
represent all the miRNA expressions that were identified. None of the miRNAs in the 
ZT19 groups illustrated significant expression differences.  
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Table 2.2: Circadian disruption induces potentially aberrant miRNA expression 
patterns. Expression patterns of all the differentially expressed miRNAs based on 
Illumina sequencing in the circadian-disrupted groups. Only the ZT specific groups that 
showed changes in miRNA expression are depicted. Colour coordination represents 
miRNAs that are part of the same gene family, cluster, or the same miRNA. 
24-Hour Acute ZT06 Expression 
rno−miR−142−5p Over 
rno−miR−150−5p Over 
rno−miR−335 Under 
rno−miR−15b−5p Over 
rno−miR−133a−3p Under 
rno−miR−1−3p Under 
24-Hour Chronic ZT06 Expression 
rno-miR-126a-5p Under 
rno−miR−30b−5p Under 
rno−let−7b−5p Over 
rno−miR−99a−5p Over 
rno−miR−10a−5p Over 
rno−let−7c−5p Over 
rno−miR−142−5p Under 
2-Week chronic ZT06  Expression 
rno−miR−146a−5p Under 
rno−miR−24−3p Under 
rno−miR−130a−3p Over 
rno−miR−127−3p Under 
rno−miR−672−5p Over 
rno−miR−193−3p Over 
rno−miR−146b−5p Under 
rno−miR−150−5p Over 
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Figure 2.5: Circadian disruption causes lowered expression of miRNAs 146a and 146b, 
and increased expression of activated NF-κB. A. Mean relative expression of miR-146a 
based on Illumina sequencing, *p-adjusted < 0.1, N=6. B. Mean relative expression of 
miR-146b based on Illumina sequencing, *p-adjusted < 0.1, N=6. C. Western 
immunoblotting images of phospho-NFκB (p65) and β-actin from a 6% SDS-PAGE gel for 
the two-week chronic ZT06 group. Images were taken with the FluorChem HD2. The five 
samples on the left represent the control samples, and the five samples on the right 
represent the circadian disrupted samples. D. Mean relative expression of the phospho-
NFκB (p65) protein based on the actin band in C, *p < 0.05, N=10. Error bars represent 
SEM.  
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Figure 2.6: Circadian disruption causes decreased expression of miR-127, and 
increased expression of Tudor-SN and BCL6.  A. Mean relative expression of miR-127 
based on Illumina sequencing, *p-adjusted < 0.1, N=6. B. Mean relative expression of 
miR-127 based on qRT-PCR data, *p < 0.05, N=10. C. Western immunoblotting images of 
BCL6, Tudor-SN, and β-actin from a 10% SDS-PAGE gel for the 2-week chronic ZT06 
group. Images were taken with the FluorChem HD2. The five samples on the left 
represent the circadian disrupted samples, and the five samples on the right represent 
the control samples. D. Mean relative expression of the BCL6 and Tudor-SN proteins 
based on the actin band in C,*P < 0.05, N=10.  
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Figure 2.7: Circadian disruption causes increased expression of STAT3. A. Western 
immunoblotting images of STAT3 and β-actin from a 10% SDS-PAGE gel for the two-
week chronic ZT06 group. Images were taken with the FluorChem HD2. The five samples 
on the left represent the circadian disrupted samples, and the five samples on the right 
represent the control samples. B. Mean relative expression of the STAT3 protein based 
on western immunoblotting data for the two-week chronic ZT06 group. Expressions 
were normalized to the actin band in A, *p < 0.05, N=10. Error bars represent SEM.  
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Figure 2.8: Circadian disruption causes increased expression of DNMT1. A. Western 
immunoblotting images of DNMT1 and β-actin from a 6% SDS-PAGE gel for the two-
week chronic ZT06 group. Images were taken with the FluorChem HD2. The five samples 
on the left represent the control samples, and the five samples on the right represent 
the circadian disrupted samples. B. Mean relative expression of the DNMT1 protein 
based on western immunoblotting data for the two-week chronic ZT06 group. 
Expressions were normalized to the actin band in A, *p < 0.05, N=10. Error bars 
represent SEM.
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CHAPTER 3: CIRCADIAN DISRUPTION-INDUCED SIGNALLING PATHWAY 
DEREGULATION IN RAT MAMMARY TISSUES 
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ABSTRACT 
   Evidence is mounting that circadian disruption (CD) is a potential carcinogen in 
breast cancer development. However, very few studies have investigated the potential 
epigenetic link in CD-induced breast cancer, and no studies have investigated the direct 
influence of CD on a broad range of transcripts in mammary tissues. Although DNA 
methylation profiles on peripheral blood samples from shift workers have identified 
changes in relevant genes, DNA methylation changes in blood are only potentially 
reflective of what is occurring in the mammary tissues. Since changes in DNA 
methylation profiles can correlate with changes in transcript levels, the current study 
utilized a proven photoperiod-shifting paradigm, various degrees of CD, and Illumina 
sequencing to investigate the direct influence of circadian disruption on transcript levels 
in the mammary tissues of a rodent model system. Even though our analysis did not 
identify any significant patterns in mRNA levels based on the degree of CD and the 
majority of groups did not show changes in gene expression on a large scale, one group 
(two-week chronic deregulation) displayed 196 differentially expressed genes, 51 of 
which have been linked to breast cancer. Through gene-specific pathway analysis, the 
data illustrate that CD may promote breast cancer development through downregulation 
of DNA repair and p53 signaling pathways, thus promoting genomic instability and 
cancer development. Although these results have to be interpreted with caution because 
only a single group illustrated drastic changes in transcript levels, they indicate that CD 
may directly induce changes in gene expression on a large scale with potentially 
malignant consequences.  
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INTRODUCTION  
  Proper regulation of gene expression is critical for normal cellular function. The 
study of epigenetics has identified several avenues that can influence the regulation of 
gene expression. A key component of the epigenome, DNA methylation can directly 
influence changes in gene expression at the transcriptional level, and changes in DNA 
methylation profiles can correlate with changes in transcript levels (Jin et al., 2011). One 
of the most abundant malignancies in the world, breast cancer is already a serious public 
concern, and evidence has been mounting that circadian disruption is a carcinogen that 
can trigger and promote the development of breast cancer (Stevens et al., 2014). 
Although numerous studies have been conducted on CD-induced breast cancer, the 
majority of these studies have focused on gene-specific analysis, and very few studies 
have investigated the effect of CD-induced changes across a broad range of genes. As a 
consequence, the direct effect of circadian disruption in mammary tissues on important 
cellular mechanisms and pathways, such as DNA damage response (DDR) and p53 
mediated signaling, remains largely unknown.  
  The DNA in every human cell is exposed to tens of thousands of aberrations per 
day, with stresses originating both endogenously and exogenously (Jackson and Bartek, 
2009; Lindahl and Barnes, 2000). Given this constant pressure, cells have evolved 
mechanisms to detect DNA lesions and to initiate repair of these lesions through signal 
pathways, with these processes being collectively called the DNA damage response 
(Jackson and Bartek, 2009). This DNA damage response is a key mechanism to ensure 
proper cellular function, and pathways related to this mechanism are frequently 
deregulated in cancers (Jackson and Bartek, 2009). Changes to DNA repair pathways in 
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tumorigenesis can vary greatly depending on different factors, such as the type of breast 
cancer and the stage of development (Davis and Lin, 2011; Li et al., 2010). However, in 
terms of tumour initiation, downregulation of DNA repair pathways has been concretely 
linked to increased genomic instability and progression of cancer (Negrini et al., 2010). 
  Cell cycle regulation and apoptosis, which are linked to the DDR system, are 
necessary for proper cellular function; when they malfunction, they can lead to cancer 
development (Reinhardt and Schumacher, 2012). Acting as a sort of failsafe system by 
initiating programmed cell death, apoptosis helps to maintain proper cell function and 
proliferation (Wong, 2011). Extensive research has shown that decreased levels of 
apoptosis is a hallmark of cancer progression, with aberrant activity of pro-apoptotic and 
anti-apoptotic proteins playing a crucial role in this process (Wong, 2011). Amongst the 
most important pro-apoptotic proteins is p53, a corner stone of tumour suppression 
activity that has been described as being the guardian of the genome because it responds 
to various stress signals and helps maintain proper cellular function (Bieging et al., 2014; 
Lane, 1992). Influencing numerous cancer-relevant pathways besides apoptosis, the p53 
signaling pathway is often aberrantly regulated in many malignancies, making it a crucial 
player in cancer development.  
  Although numerous studies have investigated links between circadian disruption 
and breast cancer, surprisingly, not many studies have investigated CD-induced changes 
through gene expression profiles in mammary tissues (Stevens et al., 2014). Amongst the 
studies that have investigated gene expression in mammary tissues in relation to circadian 
rhythms, the focus was not placed on broad gene expression profiles or circadian 
disruption, but on either the influence of mammary development or chemical induction of 
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changes to specific circadian genes within the mammary gland (Fang et al., 2010; Metz et 
al., 2006). In fact, the studies that have come closest to investigating the broad CD-
induced gene expression profile in mammary tissues have been the epigenetic 
experiments on shift worker blood samples that have provided evidence of changes in 
DNA methylation at important breast cancer relevant genes (Zhu et al., 2011). Since 
epigenetic profiles of peripheral blood samples have shown a strong correlation with 
reflective changes in mammary tissues, these DNA methylation profiles may correlate to 
transcript levels in mammary tissues (Liu et al., 2015; Widschwendter et al., 2008). 
However, these studies still do not represent a direct attempt to investigate CD-induced 
gene expression profiles in mammary tissues, and provide no direct information on the 
potential pathways and cellular mechanisms that may be affected. Therefore, given that 
transcript levels are an extension of the epigenome, this study will attempt to investigate 
the effect of varying degrees of circadian disruption on gene expression in mammary 
tissues by incorporating a proven photoperiod-shifting paradigm and a rodent model 
system.  
MATERIAL AND METHODS 
Animal model and circadian disruption paradigm 
  Female Sprague Dawley rats from Charles River (Quebec) were housed at the 
Canadian Center for Behavioural Neuroscience at the University of Lethbridge. The rats 
were housed in a sterile facility in a temperature controlled room, two per cage, and given 
food and water ad libitum. Handling and care of the animals was performed in 
accordance with the recommendations of the Canadian Council on Animal Care, and the 
procedures were approved by the University of Lethbridge Animal Welfare Committee. 
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Before the start of the experiment, all the rats were entrained to a 12-hour light-dark cycle 
for 22 days to allow entrainment to a normal light schedule. At 83 days old, the rats were 
then randomly assigned to different treatment and control groups. 
  Circadian disruption was induced by following a photoperiod-shifting paradigm 
that has been shown to cause physiological and behavioural changes in rodents (Craig 
and McDonald, 2008; Deibel et al., 2014; Devan et al., 2001; McDonald et al., 2013). In 
total, 40 female rats underwent this photoperiod-shifting (PS) paradigm. To stimulate PS, 
the colony lights were turned on three hours earlier each day. To investigate the effect of 
varying degrees of CD, the 40 rats were separated into acute and chronic circadian 
disruption groups. Twenty rats underwent acute photo-period shifting, which consisted of 
lights coming on three hours earlier each day for a total cycle time of six days. Another 
20 rats underwent chronic photoperiod-shifting, which consisted of a rotation between 
lights coming on three hours earlier each day for six days, and then ten days of a regular 
12-hour light-dark cycle, for a total cycle time of 54 days. For both the acute (6 days) and 
chronic groups (54 days), following the PS cycle, the rats were exposed to a normal 12-
hour light-dark cycle until it was time for tissue extractions.   
  The acute (20 rats) and chronic (20 rats) CD groups were then separated further 
based on the time of tissue extraction. Mammary tissue extractions occurred 24 hours and 
two weeks following acute or chronic circadian disruption, with ten rats from each CD 
group undergoing tissue extractions at each of these times. To account for and investigate 
the potential influence of specific time points within a 24-hour circadian cycle on CD-
induced breast carcinogenesis, two different tissue extraction time points, each 
corresponding to a specific zeitgeber time, were performed on each tissue extraction day 
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(24 hours and two weeks following CD). Half of the rats (five) in each tissue extraction 
group were sacrificed at ZT06 (6 hours after lights on) and the other remaining rats (five) 
from each group were sacrificed at ZT19 (19 hours after lights on). These two different 
ZT points were chosen because they represented the light and dark phases of the 
circadian cycle. 
  Both the acute (20 rats) and chronic (20) control groups were exposed to a 12-
hour light-dark cycle for either six days (acute) or 54 days (chronic). The rats from each 
CD control group were then exposed to a 12 hour light-dark cycle for either 24 hours (10 
rats) or two weeks (10 rats) depending on the time of tissue extraction for the 
corresponding experimental group. From each tissue extraction control group (10 rats), 
five rats were sacrificed at ZT06 and five rats were sacrificed at ZT19 on the 
corresponding tissue extraction day.  
  Euthanasia of the rats was performed through anesthesia with Isoflurane (4‒5 %; 
oxygen at 2 liters per minute) and decapitation by a guillotine, with euthanasia of the rats 
alternating between the control and experimental rats. The mammary glands were 
collected, immediately stored in liquid nitrogen, and stored long-term at a temperature of 
-80°C.  
Total RNA extraction 
  Whole mammary tissues were ground in liquid nitrogen using sterile, chilled 
mortars and pestles. Approximately 0.05 g of ground tissue from each sample was then 
suspended in Zymo Research tri-reagent, and lysed using two cycles of the Qiagen Tissue 
Lyser II for 2 minutes at 25 Hz. Total RNA was then extracted using the direct-zol RNA 
Miniprep kit from Zymo research (R2053). The quality of the RNA was then checked 
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using Nanodrop 2000c, and quality bio-analysis was conducted using the Agilent 2100 
and the Agilent Small RNA Kit and Chip (5067-1548), with only samples having a RIN 
value greater than eight being used in downstream applications.  
Gene expression sequencing and bioinformatics analysis 
   Three samples from each tissue extraction and ZT group for both the experimental 
and control groups were randomly chosen to undergo sequencing analysis. The TruSeq 
RNA Sample Preparation Kit V-2/SetA from Illumina (RS-122-2001) was used to 
prepare small RNA libraries from 1 µg of total RNA. qPCRs were then run to validate the 
libraries following the PCR program recommended by the Illumina RNA Sample Prep 
Kit (3 mins at 95°C; 40 cycles of 3 sec. at 95°C, 30 sec. at 60°C). Cluster generation for 
sequencing was performed using cBot and the TruSeq SR Cluster Kit v2-cBot-GA (GD-
300-2001) from Illumina. Single-read sequencing was performed using the TruSeq SBS 
Kit v5-GA (FC-104-5001) from Illumina on the Genome Analyzer GAIIx at 36 cycles.  
 Bioinformatics approaches on the sequencing data were used to define gene 
expression levels amongst the different experimental groups. Basecalling and 
demultiplexing were performed using CASAVA 1.8.1 pipeline (Illumina) with default 
settings. The quality of the libraries was evaluated using FastQC v0.10.1 software. 
Contaminating sequences (adapters, phiX, polyA, polyC, ribosomal RNA) were filtered 
out, and filtered sequence reads were aligned to the rat genome assembly Rnor 5.0 
(Ensembl) from Illumina’s iGENOME database. Files in sam format were converted to 
bam, sorted by chromosomal position, and indexed. Further quality control was 
performed using the RSeQC_2.3.7 software package, with no libraries being removed 
due to quality problems.   
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qRT-PCRs 
  Validation of the sequencing results was performed by qRT-PCR. cDNA was 
synthesized using 500 ng of RNA and the iScript Select cDNA Synthesis Kit (#170-
8897) from BioRad. The qPCRs were performed utilizing SYBR Green on the BioRad 
C1000 Thermal Cycler and CFX96 Real-Time System, by using SosoFast EvaGreen 
Supermix (#172-5201) from BioRad. Gradient PCRs were run for each primer to 
determine appropriate and optimal annealing temperatures. All qPCRs were run in 
triplicate, using 2 min at 95°C; 40 cycles of 5 sec at 95°C, 5 sec at primer specific 
temperature. Efficiency standard curves for the primers were generated using serial 
dilutions, and after all the qPCR cycling, melt curve analysis was conducted using the 
optimal parameters for the BioRad C1000 thermal cycler (65°C to 95°C, increments of 
0.5°C).  
  Forward and reverse primers for the genes of interest were designed using the 
PrimerQuest program from Integrated DNA Technologies, and the custom oligos were 
ordered from Eurofins Genomics. Based on Hvid et al. 2011, recommended reference 
genes were ordered from Eurofins Genomics with the same forward and reverse primer 
sequences. The best combination of two reference genes, ATP5b and Sdha, was found 
using the programs NormFinder (http://moma.dk/normfinder-software) and qbaseplus 
(Biogazelle), with the stability values meeting the geNorm stability cut offs (CV < 0.25, 
M-Value < 0.5).  
Statistical analyses 
  Exploratory statistical analyses on the sequencing data and outlier detection were 
performed using Array Quality Metrics, and gene set enrichment analysis was conducted 
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using GOStats. Statistical significance between the experimental and control groups was 
evaluated by one-way ANOVA. Multiple comparisons adjustment was performed using 
Benjamini-Hochberg procedure, and genes with an adjusted p-value below 0.1 were 
considered differentially expressed (Benjamini and Hochberg, 1995). The results are 
expressed as heat maps and MA plots. For the qRT-PCR data, Student’s t-test was used 
for independent variance to determine significance (p<0.05). Statistical analysis and 
plotting of the data was performed using MS Excel software for Windows. The results 
are presented as mean relative expression values ± standard error of the mean (SEM).         
RESULTS 
Circadian disruption results in the differential expression of a broad range of genes 
linked to breast cancer  
  In this study, we investigated the effect of varying degrees of circadian disruption 
on gene expression in the mammary tissues of Sprague Dawley rats. The influence of 
light dependent zeitgeber times was also incorporated to investigate possible fluctuations 
within a 24-hour circadian cycle. There were no significant patterns in gene expression 
between the various groups with regards to the degree of CD, tissue extraction time after 
CD, or ZT (Figure 3.1, Table 3.1). Although the sequencing results identified a broad 
range of differentially expressed genes, many of which are linked to breast cancer, only 
two groups illustrated more than ten changes in gene expression, the 24-hour acute ZT06 
and two-week chronic ZT19 groups (Table 3.1). The majority of these differences were 
mainly found in the two-week chronic ZT19 group, in which 196 differentially expressed 
genes were identified, 51 of which have been linked to breast cancer (Table 3.1; Figure 
3.2).  
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The CD-induced gene expression changes in the two-week chronic ZT19 group 
correlate to disturbances in breast cancer related pathways 
  To analyze the significance of the gene expression changes in the two-week 
chronic ZT19 group in terms of potential complications and breast cancer, pathway 
analysis was performed. The results illustrated that a substantial number of pathways and 
processes linked to diseases and complications were altered in these rats (Figure 3.3). 
Based on this data, gene-specific pathway analysis for some of the breast cancer-relevant 
pathways was performed to gain more details and insight into the effects of CD. The 
analysis revealed that numerous DNA repair pathways were altered: base excision repair 
(BER), homologous recombination (HR), mismatch repair (MMR), and nucleotide 
excision repair (NER) (Figures 3.4‒3.6). The overall gene expression patterns amongst 
these pathways correlated to decreased DNA repair, a hallmark in the initiation of 
tumorigenesis. Gene-specific pathway analysis was also performed on the p53 signaling 
pathway, with the gene expression patterns correlating to decreased p53 signaling, 
decreased DNA repair, and decreased apoptosis (Figure 3.7). Aberrant regulation of the 
p53 signaling pathway and decreased apoptosis is a corner stone in the development of 
most cancers, including breast cancer. 
qRT-PCR validation produces the same expression trends, but not significant 
differences 
  Validation of the sequencing results was performed on several of the differentially 
expressed genes through qRT-PCR analysis, including the Cdk1, PDK4, and Nusap1 
genes (Figure 3.8 and 3.9). Although the qRT-PCR data produced the same expression 
trends, the data did not produce significant differences (Figure 3.8 and 3.9). In general, 
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the same pattern was observed in the majority of the genes that were analyzed through 
qRT-PCR: similar expression trends, but no significant difference. These results may be 
due to the fact that the two samples that did not undergo Illumina sequencing usually 
produced qPCR expression trends that were not consistent with the sequencing data, 
while the three sequenced samples were consistent. Given that multiple reference genes 
were tested and the stability values for these genes based on recommended programs 
were well within the recommended ranges (Table 3.2), it is unlikely that the qRT-PCR 
data is unstable. This indicates that the gene expression differences based on Illumina 
sequencing in the two-week chronic ZT19 group may have been random, which would 
explain such drastic expression differences in this experimental group (Table 3.1). 
However, the qPCR expression trends are consistent when all ten samples are analyzed, 
indicating that with a larger sample size significant gene expression changes may have 
been produced through qRT-PCR.   
DISCUSSION 
  Numerous publications have provided consistent evidence that circadian 
disruption acts as a carcinogen in breast cancer development, but no studies have 
conducted large-scale gene expression profiles on CD-induced changes in mammary 
tissues. Therefore, in this study we investigated the effect of varying degrees of CD on 
gene expression in rat mammary tissues. Although our findings did not produce any 
significant patterns based on the degree of CD or tissue extraction time, one group, the 
two-week chronic ZT19 group, did experience drastic changes in gene expression, 
indicating that long-term circadian disruption may be potentially linked to a cascade of 
differential gene expression in mammary tissues (Figure 3.1 and 3.2; Table 3.1).  
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  DNA repair mechanisms are key components of the DNA damage response, and 
the sequencing data illustrated that several DNA repair pathways were aberrantly 
expressed due to CD in the two-week chronic ZT19 group (Figure 3.3). Specifically, 
gene-specific pathway analysis showed that key genes in the BER, HR, MMR, and NER 
pathways were down regulated (Figures 3.4‒3.6). Decreased DNA repair has been 
associated with increased genomic instability and progression of cancer, and these results 
show that CD may decrease DNA repair on multiple fronts (Negrini et al., 2010). 
Furthermore, amongst these repair mechanisms, homologous recombination has been 
shown to play a crucial role in breast cancer development (Helleday, 2010). HR is 
involved in double strand break (DSB) repairs, and mutations to genes involved in this 
process are linked to tumours and gene rearrangements; HR can also be viewed as a last 
resort for DNA repair if DNA lesions are not identified and mended by other repair 
mechanisms (Helleday, 2010). Gene pathway analysis illustrated that CD-induced down 
regulation of HR was associated with decreased expression of BRCA2, a tumour 
suppressor gene that has been extensively linked to breast cancer development, as well as 
lowered expression of Rad50 and Mre11, which are both key components of the MRN 
complex and are linked to increased breast cancer susceptibility (Figure 3.6) (Bartkova et 
al., 2008; Shahid et al., 2014). In addition, sequencing results illustrated significant 
decreased expression of the Nusap1 gene (Figure 3.9), which has been shown to regulate 
levels of BRCA1, an extensively studied tumour suppressor gene involved in double 
strand breaks and breast cancer (Kotian et al., 2014). These results indicate that CD-
induced breast cancer development may be linked to aberrant DNA repair through 
multiple mechanisms, with silencing of important genes involved in homologous 
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recombination possibly playing a crucial role.  
  Another pathway linked to the DDR system is the extensively studied p53 
signaling pathway, with our data showing that CD caused decreased activity in this 
pathway in the two-week chronic ZT19 group (Figure 3.3). The p53 pathway has long 
been a corner-stone of cancer research because of its important role in the cell cycle and 
apoptosis (Bieging et al., 2014). Gene expression pathway analysis on the p53 signalling 
pathway illustrated that key genes involved in this pathway were mostly down regulated, 
while the IGF gene was up regulated (Figure 3.7). Amongst the most consistently down 
regulated genes were check point kinase 1 (CHK1), CHK2, CASP8, Bid, and sestrins 
(Figure 3.7). Both CHK1 and CHK2 play a crucial role in cell cycle arrest and apoptosis 
because they are part of the DDR mechanism and can activate p53 (Jackson and Bartek, 
2009). The CASP8 and Bid genes play a role in the signaling cascade that can induce 
apoptosis, with CASP8 being able to modify Bid activity (Kooijman, 2006). The sestrin 
genes are induced by p53 upon DNA damage, help regulate stress responses to 
environmental stimuli, and have been shown to decrease tumour growth in some cancer 
cells (Lee et al., 2010). Finally, expression of the insulin-like growth factor (IGF) was up 
regulated in all three of the sequenced samples (Figure 3.7). IGF has been identified as an 
inhibitor of apoptosis in many different cell types through various mechanisms, including 
inactivation of CASP8 through FLIP activity (Kooijman, 2006). Taken together, these 
CD-induced gene expression patterns correlate with decreased apoptosis and increased 
genomic instability, indicating further contributions to cancer initiation and echoing the 
theme illustrated by the CD-induced changes in the DNA repair mechanisms previously 
discussed.  
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  Although the results discussed thus far have provided compounding evidence on 
the potential influence of CD on breast cancer development through aberrant gene 
expression patterns, only limited conclusions can be drawn because the changes are 
isolated to one group (Table 3.1). As mentioned previously, no patterns in gene 
expression changes were observed based on the degree of CD or tissue extraction times, 
with only the two-week chronic ZT19 group undergoing changes in gene expression on a 
high enough scale to significantly influence breast-cancer-relevant pathways (Table 3.1). 
Furthermore, although the qRT-PCRs generated the same expression trends as the 
sequencing results, the trends were not significant based on the qRT-PCR data (Figure 
3.8 and 3.9). Given that the qPCR reference genes were stable (Table 3.2), these results, 
coupled with the fact that the non-sequenced samples typically generated opposite 
expression patterns in the qRT-PCR data, indicate that the drastic expression trend 
identified in the two-week chronic ZT19 group may have been random, or a reflection of 
an inter-individual variability in CD responses. However, the offsetting contribution of 
the non-sequenced samples to the qRT-PCR results was not enough to alter the same 
expression trend (Figure 3.8 and 3.9). This indicates that with a larger sample size in 
every group, the same results illustrated in the two-week chronic ZT19 group may have 
been generated in the other groups as well.  
  To our knowledge, this study represented the first attempt at directly investigating 
wide range CD-induced changes to gene expression in rodent mammary tissues. 
Although the results did not produce significant patterns or findings on the influence of 
circadian disruption based on the degree of CD or tissue extraction time, the study did 
provide evidence that CD may directly induce gene expression changes on a significant 
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scale in mammary tissues. Specifically, the results indicate that circadian disruption may 
alter DNA damage response mechanisms and p53 signaling in a manner that initiates and 
promotes breast cancer development. However, based on the results, it seems that the 
small sample size may either be contributing to the generated results, or masking the 
extent of the CD-induced changes in gene expression. Therefore, repeating the 
experimental design with some slight variations and increased group size is a warranted 
future step. Although these results have to be interpreted with caution, they signify that 
aberrant CD-induced gene expression changes in mammary tissues might play a role in 
breast cancer initiation through potentially malignant changes to DNA damage response 
mechanisms and p53 signaling. 
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Figure 3.1: Heat map cluster of the Illumina gene sequencing results. All of the 
sequenced samples based on the degree of circadian disruption and tissue extraction 
times.  
86 
 
Table 3.1: Circadian disruption induces changes in gene expression. Number of genes 
differentially expressed in all the experimental groups based on the Illumina sequencing 
data.                   
Group Number of Genes Differentially Expressed 
Number of Genes linked to 
Breast Cancer 
24-hr Acute ZT06 15 12 
24-hr Acute ZT19 0 0 
2-Week Acute ZT06 0 0 
2-Week Acute ZT19 2 2 
24-hr Chronic ZT06 2 0 
24-hr Chronic ZT19 5 4 
2-Week Chronic ZT06 4 3 
2-Week Chronic ZT19 196 51 
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Figure 3.2: Circadian disruption causes large scale gene expression changes in the 2-
week chronic ZT19 group. MA plot based on the gene expression Illumina sequencing 
results for the 2-week chronic ZT19 group. The y-axis represents log fold change, while 
the x-axis represents mean expression. The plots represent all the gene expressions that 
were identified, and the red plots represent genes that showed a significant expression 
difference; P-adjusted < 0.1, N=6. 
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Figure 3.3: Circadian disruption causes changes to disease related and breast cancer 
relevant pathways in the 2-week chronic ZT19 group. Heat map cluster based on the 
gene expression Illumina sequencing results for disease related and breast cancer 
relevant pathways in the 2-week chronic ZT19 group. The red bands represent over 
expressed pathways and the green bands represent under expressed pathways. 
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Figure 3.4: Circadian disruption induced changes to the base excision repair pathway. 
Each gene is broken down into three portions and represents the three sequenced 
samples, with red correlating to overexpressed and green correlating to underexpressed 
genes. Pathways were generated using KEGG graphs and rendered by Pathview.   
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Figure 3.5: Circadian disruption induced changes to the homologous recombination 
pathway. Each gene is broken down into three portions and represents the three 
sequenced samples, with red corresponding to overexpressed and green corresponding 
to underexpressed genes. Pathways were generated using KEGG graphs and rendered 
by Pathview. 
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Figure 3.6: Circadian disruption induced changes to the mismatch repair and 
nucleotide excision repair pathways. A. Mismatch Repair pathway and B. Nucleotide 
Excision Repair pathway based on the Illumina gene sequencing results. Each gene is 
broken down into three portions and represents the three sequenced samples, with red 
correlating to overexpressed and green correlating to underexpressed genes. Pathways 
were generated using KEGG graphs and rendered by Pathview.     
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Figure 3.7: Circadian disruption induced changes to the p53 signaling pathway. Each 
gene is broken down into three portions and represents the three sequenced samples, 
with red correlating to overexpressed and green correlating to underexpressed genes. 
Pathways were generated using KEGG graphs and rendered by Pathview.   
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Figure 3.8: qRT-PCR and Illumina sequencing data for the Cdk1 and Pdk4 genes. A. 
Mean relative expression of the Cdk1 gene based on qRT-PCR, N=10. B. Mean Relative 
expression of the Cdk1 gene based on Illumina sequencing, N=6, *p-adjusted < 0.05 C. 
Mean Relative expression of the PDK4 gene based on qRT-PCR, N=10.  
D. Mean relative expression of the PDK4 gene based on Illumina sequencing, N=6, **p-
adjusted < 0.01. Error bars represent SEM. 
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Figure 3.9: qRT-PCR and Illumina sequencing data for the Nusap1 gene. A. Mean 
relative expression of the Nusap1 gene based on qRT-PCR, N=10. B. Mean Relative 
expression of the Nusap1 gene based on Illumina sequencing, N=6, *p-adjusted < 0.05. 
Error bars represent SEM. 
 
Table 3.2: Stability data for the qRT-PCR results. Normfinder stability values, and 
GeNorm coefficient and M-values for the reference genes used in the qRT-PCR analysis.  
NormFinder 
Gene Name Stability Value 
Best Combination of 
Two Genes 
Combined 
Stability Value 
ATP5b 0.027 
ATP5b and Sdha 0.032 Sdha 0.058 
Tbp 0.115 
GenNorm 
Gene Name Coefficient Variance M-Value 
ATP5b 0.0671 0.1929 
Sdha 0.0666 0.1929 
 *Cut off for acceptable stability: CV < 0.25; M-Value < 0.5.  
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS 
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  There is mounting evidence that circadian disruption (CD) is a carcinogen in the 
development of breast cancer. Given that breast cancer is already the most common 
malignancy affecting women worldwide and that one-third of the Canadian labour force 
does not work a regular daytime shift, investigating the mechanisms involved in CD-
induced breast cancer is of utmost importance. 
  Numerous studies have provided evidence of potential mechanisms linking 
circadian disruption to breast cancer development. These include case studies that 
provide indirect evidence that shift workers are at a higher risk of developing breast 
cancer, the consequences of lower nocturnal MLT levels due to CD, the involvement of 
circadian clock genes in breast cancer development, and model systems showing 
increased xenograft tumour growth due to CD (Barh et al., 2010; Blask et al., 2003; Cos 
et al., 2006; Hansen and Stevens, 2012; Haus and Smolensky, 2013; Knutsson et al., 
2013). However, despite the fact that these studies have highlighted CD-induced breast 
cancer as a warranted concern, surprisingly, very few studies have taken different 
approaches to investigating CD-induced breast cancer.  
  One of the potential new approaches to investigating CD-induced breast cancer is 
epigenetics. Two specific epigenetic mechanisms, DNA methylation and miRNAs, have 
been increasingly recognized in regard to both breast cancer development and circadian 
rhythms. Studies have shown that both DNA methylation and miRNAs are crucial 
components in breast cancer development through various mechanisms that can exert 
both oncogenic and oncostatic influences (Jovanovic et al., 2010; Koturbash et al., 2011). 
In terms of circadian rhythms, evidence shows that all the core clock genes can undergo 
aberrant promoter methylation in breast cancer and that DNA methylation may play a 
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direct role in the circadian clock (Azzi et al., 2014; Joska et al., 2014). miRNAs have 
been shown to oscillate with the circadian cycle, directly influence the expression of 
clock genes, and even reset circadian clock signalling pathways (Alvarez-Saavedra et al., 
2011; Na et al., 2009; Nagel et al., 2009).  
  Despite the evidence that epigenetics plays a role in breast cancer development 
and circadian rhythms, only a handful of studies have directly investigated the role of 
epigenetics in CD-induced breast cancer. The majority of these studies show that long-
term shift work can cause aberrant promoter DNA methylation in breast cancer relevant 
genes and miRNAs in peripheral blood cells, and one study utilized a rodent model 
system to exhibit that CD-induced xenograft tumour growth may be linked to increased 
global DNA methylation (Jacobs et al., 2013; Liu et al., 2015; Schwimmer et al., 2014; 
Shi et al., 2013; Zhu et al., 2011). However, despite the importance of these findings, all 
the studies focused on DNA methylation, varying degrees of CD and epigenetic 
fluctuations within a 24-hour circadian cycle were not investigated, and no analysis was 
conducted on mammary tissues.  
  The goal of the current study is to address these shortcomings and provide new 
insights into CD-induced breast cancer by conducting an environmentally controlled 
experiment using a rodent model system. 
  To our knowledge, our results are the first to illustrate that CD directly causes 
changes in miRNA expressions in mammary tissues and that these changes are likely 
plastic and linked to the light and dark phases of the circadian cycle. Furthermore, to our 
knowledge, this study represents the first exploratory attempt at directly investigating 
wide-range CD-induced changes to gene expression in rodent mammary tissues. 
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Our major findings are as follows: 
    1. CD directly induces expression changes in a wide range of breast cancer 
relevant miRNAs and miRNAs linked to circadian rhythms in rodent mammary tissues. 
  2. The CD-induced changes in miRNA expression are likely plastic, and this 
plasticity is linked to the degree of CD and timeframe of reentrainment. 
  3. The light and dark phase of the circadian cycle potentially influences the CD-
induced changes in miRNA expression, indicating that circadian dependent miRNA 
fluctuations should be considered when investigating CD-induced breast cancer. 
  4. CD directly induces aberrant expression changes in breast cancer relevant 
proteins, with these changes potentially being linked to the aberrant CD-induced miRNA 
expressions.  
  5. The initiation and development of CD-induced breast cancer may be linked to 
an interconnected web of increased NF-κB activity and increased levels of Tudor-SN, 
STAT3, and BCL6, with aberrant CD-induced downregulation of miR-127 and miR-146b 
potentially contributing to this dynamic. 
  6. Long-term CD can potentially induce a wide range of gene expression changes 
on a scale large enough to influence breast cancer relevant pathways.  
  7. Among the gene signalling pathways that may play a key role in the initiation 
of CD-induced breast cancer are DNA damage response pathways and p53 mediated 
signalling. 
  Interestingly, although the same CD schemes and the same tissues were used for 
analysis in both the miRNA and gene expression experiments, the results produced 
differing data in terms of the influence of CD on these processes. The miRNA results 
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produced a clear pattern of CD-induced changes among the different experimental 
groups, while the gene expression results only showed drastic gene expression changes in 
one group and no clear patterns among the experimental groups. It is important to note 
that gene transcript levels do not correlate to miRNA activity and expression in 
mammals, because translational suppression is mainly achieved through inhibitory 
machinery and not degradation. Therefore, the CD-induced changes in miRNA 
expression are not a representation of the CD-induced gene expression changes reported, 
and vice versa.         
  Given that the same tissues were analyzed in both sets of results, this opens the 
door for numerous possibilities and potential insights when interpreting the miRNA and 
gene expression data together. For example, transcript levels do correlate with changes in 
DNA methylation. Previous studies have reported changes in DNA methylation at breast 
cancer relevant promoters in shift workers, but the analysis was conducted on peripheral 
blood cells and not on mammary tissues. Although DNA methylation profiles in blood 
have been correlated to changes in mammary tissues, this still does not provide a direct 
representation of the CD-induced changes occurring in the mammary glands. Therefore, 
given our miRNA and gene expression results, it is possible that CD may not induce 
changes in DNA methylation to the same extent in mammary tissues as in peripheral 
blood cells. Of course, our gene expression results are also only a correlation in terms of 
DNA methylation levels, so direct investigation of CD-induced DNA methylation levels 
in mammary tissues is required. Furthermore, because ours was an environmentally 
controlled experiment that incorporated a rodent model system, and because there was no 
bias on the CD-induced changes through artificial MLT levels or xenografts, our results 
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represent an accurate assessment of the potential carcinogenicity of CD in breast cancer 
initiation. Based on both sets of results, it would seem that miRNA activity may play a 
prominent role in the initiation of CD-induced breast cancer, with this activity potentially 
triggering malignant downstream consequences. 
FUTURE DIRECTIONS 
  Since our results represent the first evidence of potentially direct consequences of 
aberrant CD-induced miRNA activity and the first attempt to investigate wide-scale CD-
induced changes in gene expression in mammary tissues, there are many possibilities for 
future directions. 
  1. Investigating the plasticity of CD-induced changes in miRNA expression 
through stricter CD schemes, reentrainment periods, and ZT extractions. 
  2. Investigating the specifics and details of light-dependent miRNA fluctuations 
and their potential role in CD-induced breast cancer. 
  3. Verifying potential circadian-relevant targets of the differentially expressed 
miRNAs through luciferase reporter experiments. 
  4. Incorporating the CD schemes and ZT extractions into xenograft models to 
investigate the effect of varying degrees of CD on tumour development, and investigating 
if miRNA and gene expression patterns can fluctuate in tumours based on circadian time 
points. 
  5. Investigating the effect and dynamic of miR-127 and miR-146b activity in 
varying breast cancer cell lines through knockdown or mimic experiments.   
  6. Repeating the experimental design for both the miRNA and gene expression in 
only the chronic CD groups, with larger group sizes and DNA methylation analysis. 
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    Overall, this thesis provides the first evidence that CD directly causes changes in 
miRNA expression in mammary tissues with potentially malignant consequences. 
Additionally, it represents the first attempt at investigating the direct effect of CD on 
large scale gene expression changes in mammary tissues. The results align with previous 
studies that have shown CD as a warranted concern in breast cancer development and that 
the initiation of this process may be linked to aberrant CD-induced miRNA activity in the 
mammary tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
REFERENCES 
 
Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B., and McKenna, W. G. (2008). 
Abeloff's Clinical Oncology 4th ed: Churchill Livingstone/Elsevier). 
Abrahamson, E. E., and Moore, R. Y. (2001). Suprachiasmatic nucleus in the mouse: retinal 
innervation, intrinsic organization and efferent projections. Brain research 916, 172-191. 
Alvarez-Saavedra, M., Antoun, G., Yanagiya, A., Oliva-Hernandez, R., Cornejo-Palma, D., Perez-
Iratxeta, C., Sonenberg, N., and Cheng, H. Y. (2011). miRNA-132 orchestrates chromatin 
remodeling and translational control of the circadian clock. Human molecular genetics 20, 731-
751. 
AmericanCancerSociety (2015). Breast Cancer in Men. In Cancer Facts and Figures 2015, 
Retrieved online. 
Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. 
Genome biology 11, R106. 
Annecke, K., Schmitt, M., Euler, U., Zerm, M., Paepke, D., Paepke, S., von Minckwitz, G., 
Thomssen, C., and Harbeck, N. (2008). uPA and PAI-1 in breast cancer: review of their clinical 
utility and current validation in the prospective NNBC-3 trial. Advances in clinical chemistry 45, 
31-45. 
Antle, M. C., and Silver, R. (2005). Orchestrating time: arrangements of the brain circadian clock. 
Trends in neurosciences 28, 145-151. 
Arendt, J. (2006). Melatonin and human rhythms. Chronobiology international 23, 21-37. 
Armengol, S., Arretxe, E., Rodriguez, L., Ochoa, B., Chico, Y., and Martinez, M. J. (2013). NF-
kappaB, Sp1 and NF-Y as transcriptional regulators of human SND1 gene. Biochimie 95, 735-742. 
Azzi, A., Dallmann, R., Casserly, A., Rehrauer, H., Patrignani, A., Maier, B., Kramer, A., and Brown, 
S. A. (2014). Circadian behavior is light-reprogrammed by plastic DNA methylation. Nature 
neuroscience 17, 377-382. 
Barh, D., Malhotra, R., Ravi, B., and Sindhurani, P. (2010). MicroRNA let-7: an emerging next-
generation cancer therapeutic. Current oncology (Toronto, Ont) 17, 70-80. 
Bartkova, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., Mistrik, M., 
Aittomaki, K., Blomqvist, C., Heikkila, P., et al. (2008). Aberrations of the MRE11-RAD50-NBS1 
DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-
predisposing gene. Molecular oncology 2, 296-316. 
Benitez-King, G., Huerto-Delgadillo, L., and Anton-Tay, F. (1993). Binding of 3H-melatonin to 
calmodulin. Life sciences 53, 201-207. 
Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B 
(Methodological) 57, 289-300. 
Bhaumik, D., Scott, G. K., Schokrpur, S., Patil, C. K., Campisi, J., and Benz, C. C. (2008). Expression 
of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast 
cancer cells. Oncogene 27, 5643-5647. 
Bieging, K. T., Mello, S. S., and Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated 
tumour suppression. Nature reviews Cancer 14, 359-370. 
Blanco, M. A., Aleckovic, M., Hua, Y., Li, T., Wei, Y., Xu, Z., Cristea, I. M., and Kang, Y. (2011). 
Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-
interacting protein with metastasis-promoting functions. The Journal of biological chemistry 
286, 19982-19992. 
Blask, D. E. (2009). Melatonin, sleep disturbance and cancer risk. Sleep medicine reviews 13, 
257-264. 
103 
 
Blask, D. E., Dauchy, R. T., Sauer, L. A., Krause, J. A., and Brainard, G. C. (2003). Growth and fatty 
acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant 
light-induced nocturnal melatonin suppression. Breast cancer research and treatment 79, 313-
320. 
Brena, R. M., and Costello, J. F. (2007). Genome-epigenome interactions in cancer. Human 
molecular genetics 16 Spec No 1, R96-105. 
Britten, A., Rossier, C., Taright, N., Ezra, P., and Bourgier, C. (2013). Genomic classifications and 
radiotherapy for breast cancer. European journal of pharmacology 717, 67-70. 
Butler, M. P., and Silver, R. (2009). Basis of robustness and resilience in the suprachiasmatic 
nucleus: individual neurons form nodes in circuits that cycle daily. Journal of biological rhythms 
24, 340-352. 
Campisi, J. (2013). Aging, cellular senescence, and cancer. Annual review of physiology 75, 685-
705. 
Chen-Goodspeed, M., and Lee, C. C. (2007). Tumor suppression and circadian function. Journal 
of biological rhythms 22, 291-298. 
Chen, C. Z., Li, L., Lodish, H. F., and Bartel, D. P. (2004a). MicroRNAs modulate hematopoietic 
lineage differentiation. Science 303, 83-86. 
Chen, H., Chung, S., and Sukumar, S. (2004b). HOXA5-induced apoptosis in breast cancer cells is 
mediated by caspases 2 and 8. Molecular and cellular biology 24, 924-935. 
Chen, J., Wang, M., Guo, M., Xie, Y., and Cong, Y. S. (2013a). miR-127 regulates cell proliferation 
and senescence by targeting BCL6. PloS one 8, e80266. 
Chen, S. T., Choo, K. B., Hou, M. F., Yeh, K. T., Kuo, S. J., and Chang, J. G. (2005). Deregulated 
expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26, 1241-1246. 
Chen, Y., Wang, J., Wang, X., Liu, X., Li, H., Lv, Q., Zhu, J., Wei, B., and Tang, Y. (2013b). STAT3, a 
Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. Journal 
of breast cancer 16, 40-49. 
Cheng, H. Y., Papp, J. W., Varlamova, O., Dziema, H., Russell, B., Curfman, J. P., Nakazawa, T., 
Shimizu, K., Okamura, H., Impey, S., and Obrietan, K. (2007). microRNA modulation of circadian-
clock period and entrainment. Neuron 54, 813-829. 
Chung, S. S., Giehl, N., Wu, Y., and Vadgama, J. V. (2014). STAT3 activation in HER2-
overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell 
traits. International journal of oncology 44, 403-411. 
Cos, S., Mediavilla, D., Martinez-Campa, C., Gonzalez, A., Alonso-Gonzalez, C., and Sanchez-
Barcelo, E. J. (2006). Exposure to light-at-night increases the growth of DMBA-induced 
mammary adenocarcinomas in rats. Cancer letters 235, 266-271. 
Coticchia, C. M., Revankar, C. M., Deb, T. B., Dickson, R. B., and Johnson, M. D. (2009). 
Calmodulin modulates Akt activity in human breast cancer cell lines. Breast cancer research and 
treatment 115, 545-560. 
Craig, L. A., and McDonald, R. J. (2008). Chronic disruption of circadian rhythms impairs 
hippocampal memory in the rat. Brain research bulletin 76, 141-151. 
Cui, W., Zhang, S., Shan, C., Zhou, L., and Zhou, Z. (2013). microRNA-133a regulates the cell cycle 
and proliferation of breast cancer cells by targeting epidermal growth factor receptor through 
the EGFR/Akt signaling pathway. The FEBS journal 280, 3962-3974. 
Davis, J. D., and Lin, S. Y. (2011). DNA damage and breast cancer. World journal of clinical 
oncology 2, 329-338. 
Davoren, P. A., McNeill, R. E., Lowery, A. J., Kerin, M. J., and Miller, N. (2008). Identification of 
suitable endogenous control genes for microRNA gene expression analysis in human breast 
cancer. BMC molecular biology 9, 76. 
104 
 
De Smet, C., Loriot, A., and Boon, T. (2004). Promoter-dependent mechanism leading to 
selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Molecular and 
cellular biology 24, 4781-4790. 
Deibel, S. H., Hong, N. S., Himmler, S. M., and McDonald, R. J. (2014). The effects of chronic 
photoperiod shifting on the physiology of female Long-Evans rats. Brain research bulletin 103, 
72-81. 
Demers, P. A., Wong I., and McLeod C. (2010). The prevelance of shift work in Canada. Paper 
presented at: the Scientific Symposium on the Health Effect of Shift Work. (Toronto, ON, April 
12, 2010). 
Devan, B. D., Goad, E. H., Petri, H. L., Antoniadis, E. A., Hong, N. S., Ko, C. H., Leblanc, L., Lebovic, 
S. S., Lo, Q., Ralph, M. R., and McDonald, R. J. (2001). Circadian phase-shifted rats show normal 
acquisition but impaired long-term retention of place information in the water task. 
Neurobiology of learning and memory 75, 51-62. 
Ehrlich, M. (2009). DNA hypomethylation in cancer cells. Epigenomics 1, 239-259. 
Eide, E. J., Woolf, M. F., Kang, H., Woolf, P., Hurst, W., Camacho, F., Vielhaber, E. L., Giovanni, A., 
and Virshup, D. M. (2005). Control of mammalian circadian rhythm by CKIepsilon-regulated 
proteasome-mediated PER2 degradation. Molecular and cellular biology 25, 2795-2807. 
Emde, A. K., Grunert, M., Weese, D., Reinert, K., and Sperling, S. R. (2010). MicroRazerS: rapid 
alignment of small RNA reads. Bioinformatics (Oxford, England) 26, 123-124. 
Etoh, T., Kanai, Y., Ushijima, S., Nakagawa, T., Nakanishi, Y., Sasako, M., Kitano, S., and Hirohashi, 
S. (2004). Increased DNA methyltransferase 1 (DNMT1) protein expression correlates 
significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple 
CpG islands in gastric cancers. The American journal of pathology 164, 689-699. 
Euhus, D. M., Bu, D., Milchgrub, S., Xie, X. J., Bian, A., Leitch, A. M., and Lewis, C. M. (2008). DNA 
methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive Oncology 17, 1051-1059. 
Fang, M. Z., Zhang, X., and Zarbl, H. (2010). Methylselenocysteine resets the rhythmic expression 
of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo. Cancer 
prevention research 3, 640-652. 
Feinberg, A. P., and Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human 
cancers from their normal counterparts. Nature 301, 89-92. 
Feng, W., Shen, L., Wen, S., Rosen, D. G., Jelinek, J., Hu, X., Huan, S., Huang, M., Liu, J., Sahin, A. 
A., et al. (2007). Correlation between CpG methylation profiles and hormone receptor status in 
breast cancers. Breast cancer research : BCR 9, R57. 
Ferguson, A. T., Lapidus, R. G., Baylin, S. B., and Davidson, N. E. (1995). Demethylation of the 
estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate 
estrogen receptor gene expression. Cancer research 55, 2279-2283. 
Folkard, S. (2008). Do permanent night workers show circadian adjustment? A review based on 
the endogenous melatonin rhythm. Chronobiology international 25, 215-224. 
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., and Lund, A. H. (2008). 
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in 
breast cancer cells. The Journal of biological chemistry 283, 1026-1033. 
Fu, A., Leaderer, D., Zheng, T., Hoffman, A. E., Stevens, R. G., and Zhu, Y. (2012). Genetic and 
epigenetic associations of circadian gene TIMELESS and breast cancer risk. Molecular 
carcinogenesis 51, 923-929. 
Fu, L., Pelicano, H., Liu, J., Huang, P., and Lee, C. (2002). The circadian gene Period2 plays an 
important role in tumor suppression and DNA damage response in vivo. Cell 111, 41-50. 
105 
 
Fujita, S., and Iba, H. (2008). Putative promoter regions of miRNA genes involved in 
evolutionarily conserved regulatory systems among vertebrates. Bioinformatics (Oxford, 
England) 24, 303-308. 
Gadducci, A., Biglia, N., Sismondi, P., and Genazzani, A. R. (2005). Breast cancer and sex steroids: 
critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, 
chemoprevention and endocrine treatment of breast cancer. Gynecological endocrinology : the 
official journal of the International Society of Gynecological Endocrinology 20, 343-360. 
Gery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D., and Koeffler, H. P. (2006). The circadian gene 
per1 plays an important role in cell growth and DNA damage control in human cancer cells. 
Molecular cell 22, 375-382. 
Gery, S., Virk, R. K., Chumakov, K., Yu, A., and Koeffler, H. P. (2007). The clock gene Per2 links the 
circadian system to the estrogen receptor. Oncogene 26, 7916-7920. 
Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G., and Hortobagyi, G. N. (2004). Breast 
carcinoma in men: a population-based study. Cancer 101, 51-57. 
Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and 
Caldas, C. (2010). Systematic comparison of microarray profiling, real-time PCR, and next-
generation sequencing technologies for measuring differential microRNA expression. Rna 16, 
991-1006. 
Goke, R., Barth, P., Schmidt, A., Samans, B., and Lankat-Buttgereit, B. (2004). Programmed cell 
death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). American journal of 
physiology Cell physiology 287, C1541-1546. 
Goll, M. G., and Bestor, T. H. (2005). Eukaryotic cytosine methyltransferases. Annual review of 
biochemistry 74, 481-514. 
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., and Song, E. (2011). Up-
regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal 
of biological chemistry 286, 19127-19137. 
Griffiths-Jones, S., Saini, H. K., van Dongen, S., and Enright, A. J. (2008). miRBase: tools for 
microRNA genomics. Nucleic acids research 36, D154-158. 
Hansen, J., and Stevens, R. G. (2012). Case-control study of shift-work and breast cancer risk in 
Danish nurses: impact of shift systems. European journal of cancer 48, 1722-1729. 
Hata, K., Okano, M., Lei, H., and Li, E. (2002). Dnmt3L cooperates with the Dnmt3 family of de 
novo DNA methyltransferases to establish maternal imprints in mice. Development (Cambridge, 
England) 129, 1983-1993. 
Haus, E., and Smolensky, M. (2006). Biological clocks and shift work: circadian dysregulation and 
potential long-term effects. Cancer causes & control : CCC 17, 489-500. 
Haus, E. L., and Smolensky, M. H. (2013). Shift work and cancer risk: potential mechanistic roles 
of circadian disruption, light at night, and sleep deprivation. Sleep medicine reviews 17, 273-
284. 
Helbig, G., Christopherson, K. W., 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., 
Broxmeyer, H. E., and Nakshatri, H. (2003). NF-kappaB promotes breast cancer cell migration 
and metastasis by inducing the expression of the chemokine receptor CXCR4. The Journal of 
biological chemistry 278, 21631-21638. 
Helleday, T. (2010). Homologous recombination in cancer development, treatment and 
development of drug resistance. Carcinogenesis 31, 955-960. 
Hoesel, B., and Schmid, J. A. (2013). The complexity of NF-kappaB signaling in inflammation and 
cancer. Molecular cancer 12, 86. 
106 
 
Hoffman, A. E., Yi, C. H., Zheng, T., Stevens, R. G., Leaderer, D., Zhang, Y., Holford, T. R., Hansen, 
J., Paulson, J., and Zhu, Y. (2010a). CLOCK in breast tumorigenesis: genetic, epigenetic, and 
transcriptional profiling analyses. Cancer research 70, 1459-1468. 
Hoffman, A. E., Zheng, T., Yi, C. H., Stevens, R. G., Ba, Y., Zhang, Y., Leaderer, D., Holford, T., 
Hansen, J., and Zhu, Y. (2010b). The core circadian gene Cryptochrome 2 influences breast 
cancer risk, possibly by mediating hormone signaling. Cancer prevention research 3, 539-548. 
Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., 
Kuan, S., Edsall, L. E., et al. (2012). Global DNA hypomethylation coupled to repressive 
chromatin domain formation and gene silencing in breast cancer. Genome research 22, 246-258. 
Hormozdiari, F., Alkan, C., Ventura, M., Hajirasouliha, I., Malig, M., Hach, F., Yorukoglu, D., Dao, 
P., Bakhshi, M., Sahinalp, S. C., and Eichler, E. E. (2011). Alu repeat discovery and 
characterization within human genomes. Genome research 21, 840-849. 
Hu, Y., Zhu, Q., and Tang, L. (2014). MiR-99a antitumor activity in human breast cancer cells 
through targeting of mTOR expression. PloS one 9, e92099. 
Hutvagner, G., and Zamore, P. D. (2002). RNAi: nature abhors a double-strand. Current opinion 
in genetics & development 12, 225-232. 
Hwang, H. W., and Mendell, J. T. (2006). MicroRNAs in cell proliferation, cell death, and 
tumorigenesis. British journal of cancer 94, 776-780. 
IARC (2012). World cancer factsheet. In World Health Organization online database,  (Retrieved 
online). 
Izadi, P., Noruzinia, M., Karimipoor, M., Karbassian, M. H., and Akbari, M. T. (2012). Promoter 
hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity 
in Iranian patients with sporadic breast cancer. Cell journal 14, 102-109. 
Jackson, S. P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. 
Nature 461, 1071-1078. 
Jacobs, D. I., Hansen, J., Fu, A., Stevens, R. G., Tjonneland, A., Vogel, U. B., Zheng, T., and Zhu, Y. 
(2013). Methylation alterations at imprinted genes detected among long-term shiftworkers. 
Environmental and molecular mutagenesis 54, 141-146. 
Jang, E. R., Lim, S. J., Lee, E. S., Jeong, G., Kim, T. Y., Bang, Y. J., and Lee, J. S. (2004). The histone 
deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer 
cells to tamoxifen. Oncogene 23, 1724-1736. 
Jiang, G., Plo, I., Wang, T., Rahman, M., Cho, J. H., Yang, E., Lopez, B. S., and Xia, F. (2013). 
BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand 
breaks in the G1 phase of the cell cycle. The Journal of biological chemistry 288, 8966-8976. 
Jin, B., Li, Y., and Robertson, K. D. (2011). DNA methylation: superior or subordinate in the 
epigenetic hierarchy? Genes & cancer 2, 607-617. 
Joska, T. M., Zaman, R., and Belden, W. J. (2014). Regulated DNA methylation and the circadian 
clock: implications in cancer. Biology 3, 560-577. 
Jovanovic, J., Ronneberg, J. A., Tost, J., and Kristensen, V. (2010). The epigenetics of breast 
cancer. Molecular oncology 4, 242-254. 
Jung, C. H., Kim, E. M., Park, J. K., Hwang, S. G., Moon, S. K., Kim, W. J., and Um, H. D. (2013). 
Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 
signaling pathway. Oncology reports 29, 2109-2113. 
Kalluri, R., and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The 
Journal of clinical investigation 119, 1420-1428. 
Kendellen, M. F., Bradford, J. W., Lawrence, C. L., Clark, K. S., and Baldwin, A. S. (2014). 
Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. 
Oncogene 33, 1297-1305. 
107 
 
Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003). Functional siRNAs and miRNAs exhibit 
strand bias. Cell 115, 209-216. 
Kitkumthorn, N., and Mutirangura, A. (2011). Long interspersed nuclear element-1 
hypomethylation in cancer: biology and clinical applications. Clinical epigenetics 2, 315-330. 
Klose, R. J., and Bird, A. P. (2006). Genomic DNA methylation: the mark and its mediators. 
Trends in biochemical sciences 31, 89-97. 
Knutsson, A., Alfredsson, L., Karlsson, B., Akerstedt, T., Fransson, E. I., Westerholm, P., and 
Westerlund, H. (2013). Breast cancer among shift workers: results of the WOLF longitudinal 
cohort study. Scandinavian journal of work, environment & health 39, 170-177. 
Ko, C. H., and Takahashi, J. S. (2006). Molecular components of the mammalian circadian clock. 
Human molecular genetics 15 Spec No 2, R271-277. 
Kooijman, R. (2006). Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine & 
growth factor reviews 17, 305-323. 
Korkmaz, A., Topal, T., Tan, D. X., and Reiter, R. J. (2009). Role of melatonin in metabolic 
regulation. Reviews in endocrine & metabolic disorders 10, 261-270. 
Kotian, S., Banerjee, T., Lockhart, A., Huang, K., Catalyurek, U. V., and Parvin, J. D. (2014). 
NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels. Cancer 
biology & therapy 15, 533-543. 
Koturbash, I., Zemp, F. J., Pogribny, I., and Kovalchuk, O. (2011). Small molecules with big 
effects: the role of the microRNAome in cancer and carcinogenesis. Mutation research 722, 94-
105. 
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., and 
Pogribny, I. P. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer 
cells to chemotherapeutic drug doxorubicin. Molecular cancer therapeutics 7, 2152-2159. 
Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. Nature reviews Genetics 11, 597-610. 
Kuruma, H., Kamata, Y., Takahashi, H., Igarashi, K., Kimura, T., Miki, K., Miki, J., Sasaki, H., 
Hayashi, N., and Egawa, S. (2009). Staphylococcal nuclease domain-containing protein 1 as a 
potential tissue marker for prostate cancer. The American journal of pathology 174, 2044-2050. 
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). 
Identification of tissue-specific microRNAs from mouse. Current biology : CB 12, 735-739. 
Lamb, R., Ablett, M. P., Spence, K., Landberg, G., Sims, A. H., and Clarke, R. B. (2013). Wnt 
pathway activity in breast cancer sub-types and stem-like cells. PloS one 8, e67811. 
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., 
Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and analysis of the human genome. 
Nature 409, 860-921. 
Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16. 
Lapidus, R. G., Ferguson, A. T., Ottaviano, Y. L., Parl, F. F., Smith, H. S., Weitzman, S. A., Baylin, S. 
B., Issa, J. P., and Davidson, N. E. (1996). Methylation of estrogen and progesterone receptor 
gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression 
in breast tumors. Clinical cancer research : an official journal of the American Association for 
Cancer Research 2, 805-810. 
Lee, J. H., Bodmer, R., Bier, E., and Karin, M. (2010). Sestrins at the crossroad between stress and 
aging. Aging 2, 369-374. 
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., Kim, S., and 
Kim, V. N. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-
419. 
108 
 
Lee, Y., Jeon, K., Lee, J. T., Kim, S., and Kim, V. N. (2002). MicroRNA maturation: stepwise 
processing and subcellular localization. The EMBO journal 21, 4663-4670. 
Lee, Y., Kim, M., Han, J., Yeom, K. H., Lee, S., Baek, S. H., and Kim, V. N. (2004). MicroRNA genes 
are transcribed by RNA polymerase II. The EMBO journal 23, 4051-4060. 
Leis, O., Eguiara, A., Lopez-Arribillaga, E., Alberdi, M. J., Hernandez-Garcia, S., Elorriaga, K., 
Pandiella, A., Rezola, R., and Martin, A. G. (2012). Sox2 expression in breast tumours and 
activation in breast cancer stem cells. Oncogene 31, 1354-1365. 
Li, S. X., Sjolund, A., Harris, L., and Sweasy, J. B. (2010). DNA repair and personalized breast 
cancer therapy. Environmental and molecular mutagenesis 51, 897-908. 
Li, Y., Meeran, S. M., Patel, S. N., Chen, H., Hardy, T. M., and Tollefsbol, T. O. (2013). Epigenetic 
reactivation of estrogen receptor-alpha (ERalpha) by genistein enhances hormonal therapy 
sensitivity in ERalpha-negative breast cancer. Molecular cancer 12, 9. 
Liang, G., Chan, M. F., Tomigahara, Y., Tsai, Y. C., Gonzales, F. A., Li, E., Laird, P. W., and Jones, P. 
A. (2002). Cooperativity between DNA methyltransferases in the maintenance methylation of 
repetitive elements. Molecular and cellular biology 22, 480-491. 
Lieberman, H. B., Bernstock, J. D., Broustas, C. G., Hopkins, K. M., Leloup, C., and Zhu, A. (2011). 
The role of RAD9 in tumorigenesis. Journal of molecular cell biology 3, 39-43. 
Lim, L. P., Lau, N. C., Weinstein, E. G., Abdelhakim, A., Yekta, S., Rhoades, M. W., Burge, C. B., 
and Bartel, D. P. (2003). The microRNAs of Caenorhabditis elegans. Genes & development 17, 
991-1008. 
Lindahl, T., and Barnes, D. E. (2000). Repair of endogenous DNA damage. Cold Spring Harbor 
symposia on quantitative biology 65, 127-133. 
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., Nery, J. R., Lee, 
L., Ye, Z., Ngo, Q. M., et al. (2009). Human DNA methylomes at base resolution show widespread 
epigenomic differences. Nature 462, 315-322. 
Liu, C. G., Calin, G. A., Volinia, S., and Croce, C. M. (2008a). MicroRNA expression profiling using 
microarrays. Nature protocols 3, 563-578. 
Liu, C. G., Spizzo, R., Calin, G. A., and Croce, C. M. (2008b). Expression profiling of microRNA 
using oligo DNA arrays. Methods (San Diego, Calif) 44, 22-30. 
Liu, J., Valencia-Sanchez, M. A., Hannon, G. J., and Parker, R. (2005). MicroRNA-dependent 
localization of targeted mRNAs to mammalian P-bodies. Nature cell biology 7, 719-723. 
Liu, K., and Wang, R. (2012). MicroRNA-mediated regulation in the mammalian circadian 
rhythm. Journal of theoretical biology 304, 103-110. 
Liu, R., Jacobs, D. I., Hansen, J., Fu, A., Stevens, R. G., and Zhu, Y. (2015). Aberrant methylation of 
miR-34b is associated with long-term shiftwork: a potential mechanism for increased breast 
cancer susceptibility. Cancer causes & control : CCC 26, 171-178. 
Lowrey, P. L., Shimomura, K., Antoch, M. P., Yamazaki, S., Zemenides, P. D., Ralph, M. R., 
Menaker, M., and Takahashi, J. S. (2000). Positional syntenic cloning and functional 
characterization of the mammalian circadian mutation tau. Science 288, 483-492. 
Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., 
Mao, M., et al. (1999). The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and 
induces apoptosis and anoikis in breast cancer cells. Oncogene 18, 7034-7045. 
Mao, Y., Fu, A., Leaderer, D., Zheng, T., Chen, K., and Zhu, Y. (2013). Potential cancer-related role 
of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC cancer 
13, 498. 
Matsuo, T., Yamaguchi, S., Mitsui, S., Emi, A., Shimoda, F., and Okamura, H. (2003). Control 
mechanism of the circadian clock for timing of cell division in vivo. Science 302, 255-259. 
109 
 
McDonald, R. J., Zelinski, E. L., Keeley, R. J., Sutherland, D., Fehr, L., and Hong, N. S. (2013). 
Multiple effects of circadian dysfunction induced by photoperiod shifts: alterations in context 
memory and food metabolism in the same subjects. Physiology & behavior 118, 14-24. 
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and 
Sidransky, D. (1995). 5' CpG island methylation is associated with transcriptional silencing of the 
tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature medicine 1, 686-692. 
Metz, R. P., Qu, X., Laffin, B., Earnest, D., and Porter, W. W. (2006). Circadian clock and cell cycle 
gene expression in mouse mammary epithelial cells and in the developing mouse mammary 
gland. Developmental dynamics : an official publication of the American Association of 
Anatomists 235, 263-271. 
Monsees, G. M., Kraft, P., Hankinson, S. E., Hunter, D. J., and Schernhammer, E. S. (2012). 
Circadian genes and breast cancer susceptibility in rotating shift workers. International journal 
of cancer Journal international du cancer 131, 2547-2552. 
Morini, M., Astigiano, S., Gitton, Y., Emionite, L., Mirisola, V., Levi, G., and Barbieri, O. (2010). 
Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of 
the human breast cancer cell line MDA-MB-231. BMC cancer 10, 649. 
Mourits, M. J., De Vries, E. G., Willemse, P. H., Ten Hoor, K. A., Hollema, H., and Van der Zee, A. 
G. (2001). Tamoxifen treatment and gynecologic side effects: a review. Obstetrics and 
gynecology 97, 855-866. 
Na, Y. J., Sung, J. H., Lee, S. C., Lee, Y. J., Choi, Y. J., Park, W. Y., Shin, H. S., and Kim, J. H. (2009). 
Comprehensive analysis of microRNA-mRNA co-expression in circadian rhythm. Experimental & 
molecular medicine 41, 638-647. 
Nagel, R., Clijsters, L., and Agami, R. (2009). The miRNA-192/194 cluster regulates the Period 
gene family and the circadian clock. The FEBS journal 276, 5447-5455. 
Nakamura, W., Yamazaki, S., Takasu, N. N., Mishima, K., and Block, G. D. (2005). Differential 
response of Period 1 expression within the suprachiasmatic nucleus. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 25, 5481-5487. 
Negrini, S., Gorgoulis, V. G., and Halazonetis, T. D. (2010). Genomic instability--an evolving 
hallmark of cancer. Nature reviews Molecular cell biology 11, 220-228. 
Nohata, N., Hanazawa, T., Enokida, H., and Seki, N. (2012). microRNA-1/133a and microRNA-
206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3, 9-21. 
Novak, P., Jensen, T., Oshiro, M. M., Watts, G. S., Kim, C. J., and Futscher, B. W. (2008). 
Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer 
research 68, 8616-8625. 
Pakneshan, P., Tetu, B., and Rabbani, S. A. (2004). Demethylation of urokinase promoter as a 
prognostic marker in patients with breast carcinoma. Clinical cancer research : an official journal 
of the American Association for Cancer Research 10, 3035-3041. 
Pan, C., Chen, H., Wang, L., Yang, S., Fu, H., Zheng, Y., Miao, M., and Jiao, B. (2012). Down-
regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. PloS one 
7, e39151. 
Park, S. Y., Seo, A. N., Jung, H. Y., Gwak, J. M., Jung, N., Cho, N. Y., and Kang, G. H. (2014). Alu 
and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer. PloS 
one 9, e100429. 
Parker, L. L., and Piwnica-Worms, H. (1992). Inactivation of the p34cdc2-cyclin B complex by the 
human WEE1 tyrosine kinase. Science 257, 1955-1957. 
Parl, F. F., Dawling, S., Roodi, N., and Crooke, P. S. (2009). Estrogen metabolism and breast 
cancer: a risk model. Annals of the New York Academy of Sciences 1155, 68-75. 
110 
 
Pegoraro, M., and Tauber, E. (2008). The role of microRNAs (miRNA) in circadian rhythmicity. 
Journal of genetics 87, 505-511. 
Rabstein, S., Harth, V., Pesch, B., Pallapies, D., Lotz, A., Justenhoven, C., Baisch, C., Schiffermann, 
M., Haas, S., Fischer, H. P., et al. (2013). Night work and breast cancer estrogen receptor status--
results from the German GENICA study. Scandinavian journal of work, environment & health 39, 
448-455. 
Ranganna, K., Mathew, O. P., Milton, S. G., and Hayes, B. E. (2013). MicroRNAome of Vascular 
Smooth Muscle Cells: Potential for MicroRNA-Based Vascular Therapies). 
Reinhardt, H. C., and Schumacher, B. (2012). The p53 network: cellular and systemic DNA 
damage responses in aging and cancer. Trends in genetics : TIG 28, 128-136. 
Reiter, R. J. (2004). Mechanisms of cancer inhibition by melatonin. Journal of pineal research 37, 
213-214. 
Reppert, S. M., and Weaver, D. R. (2002). Coordination of circadian timing in mammals. Nature 
418, 935-941. 
Rodier, F., and Campisi, J. (2011). Four faces of cellular senescence. The Journal of cell biology 
192, 547-556. 
Rodriguez, A., Griffiths-Jones, S., Ashurst, J. L., and Bradley, A. (2004). Identification of 
mammalian microRNA host genes and transcription units. Genome research 14, 1902-1910. 
Salminen, A., Kauppinen, A., Hiltunen, M., and Kaarniranta, K. (2014). Epigenetic regulation of 
ASC/TMS1 expression: potential role in apoptosis and inflammasome function. Cellular and 
molecular life sciences : CMLS 71, 1855-1864. 
Sauer, L. A., Dauchy, R. T., and Blask, D. E. (2001). Melatonin inhibits fatty acid transport in 
inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated 
signal transduction. Life sciences 68, 2835-2844. 
Scadden, A. D. (2005). The RISC subunit Tudor-SN binds to hyper-edited double-stranded RNA 
and promotes its cleavage. Nature structural & molecular biology 12, 489-496. 
Schwimmer, H., Metzer, A., Pilosof, Y., Szyf, M., Machnes, Z. M., Fares, F., Harel, O., and Haim, A. 
(2014). Light at night and melatonin have opposite effects on breast cancer tumors in mice 
assessed by growth rates and global DNA methylation. Chronobiology international 31, 144-150. 
Shackney, S. E., and Silverman, J. F. (2003). Molecular evolutionary patterns in breast cancer. 
Advances in anatomic pathology 10, 278-290. 
Shahid, T., Soroka, J., Kong, E. H., Malivert, L., McIlwraith, M. J., Pape, T., West, S. C., and Zhang, 
X. (2014). Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor. 
Nature structural & molecular biology 21, 962-968. 
Shann, Y. J., Cheng, C., Chiao, C. H., Chen, D. T., Li, P. H., and Hsu, M. T. (2008). Genome-wide 
mapping and characterization of hypomethylated sites in human tissues and breast cancer cell 
lines. Genome research 18, 791-801. 
Shi, F., Chen, X., Fu, A., Hansen, J., Stevens, R., Tjonneland, A., Vogel, U. B., Zheng, T., and Zhu, Y. 
(2013). Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers. 
Environmental and molecular mutagenesis 54, 406-413. 
Shostak, K., and Chariot, A. (2011). NF-kappaB, stem cells and breast cancer: the links get 
stronger. Breast cancer research : BCR 13, 214. 
Shvarts, A., Brummelkamp, T. R., Scheeren, F., Koh, E., Daley, G. Q., Spits, H., and Bernards, R. 
(2002). A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-
p53 signaling. Genes & development 16, 681-686. 
Sigal, A., and Rotter, V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons 
of the guardian of the genome. Cancer research 60, 6788-6793. 
111 
 
Silver, R., Romero, M. T., Besmer, H. R., Leak, R., Nunez, J. M., and LeSauter, J. (1996). Calbindin-
D28K cells in the hamster SCN express light-induced Fos. Neuroreport 7, 1224-1228. 
Simpson, P. T., Reis-Filho, J. S., Gale, T., and Lakhani, S. R. (2005). Molecular evolution of breast 
cancer. The Journal of pathology 205, 248-254. 
Sire, C., Moreno, A. B., Garcia-Chapa, M., Lopez-Moya, J. J., and San Segundo, B. (2009). Diurnal 
oscillation in the accumulation of Arabidopsis microRNAs, miR167, miR168, miR171 and miR398. 
FEBS letters 583, 1039-1044. 
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K., Sethi, G., and 
Bishayee, A. (2014). Targeting the STAT3 signaling pathway in cancer: role of synthetic and 
natural inhibitors. Biochimica et biophysica acta 1845, 136-154. 
Soto-Vega, E., Meza, I., Ramirez-Rodriguez, G., and Benitez-King, G. (2004). Melatonin stimulates 
calmodulin phosphorylation by protein kinase C. Journal of pineal research 37, 98-106. 
Stevens, R. G. (2009). Light-at-night, circadian disruption and breast cancer: assessment of 
existing evidence. International journal of epidemiology 38, 963-970. 
Stevens, R. G., Brainard, G. C., Blask, D. E., Lockley, S. W., and Motta, M. E. (2014). Breast cancer 
and circadian disruption from electric lighting in the modern world. CA: a cancer journal for 
clinicians 64, 207-218. 
Stinson, S., Lackner, M. R., Adai, A. T., Yu, N., Kim, H. J., O'Brien, C., Spoerke, J., Jhunjhunwala, S., 
Boyd, Z., Januario, T., et al. (2011). TRPS1 targeting by miR-221/222 promotes the epithelial-to-
mesenchymal transition in breast cancer. Science signaling 4, ra41. 
Storch, K. F., Lipan, O., Leykin, I., Viswanathan, N., Davis, F. C., Wong, W. H., and Weitz, C. J. 
(2002). Extensive and divergent circadian gene expression in liver and heart. Nature 417, 78-83. 
Thomson, D. W., Bracken, C. P., and Goodall, G. J. (2011). Experimental strategies for microRNA 
target identification. Nucleic acids research 39, 6845-6853. 
Tsutsui, S., Ohno, S., Murakami, S., Hachitanda, Y., and Oda, S. (2002). Prognostic value of c-
erbB2 expression in breast cancer. Journal of surgical oncology 79, 216-223. 
Veeck, J., Wild, P. J., Fuchs, T., Schuffler, P. J., Hartmann, A., Knuchel, R., and Dahl, E. (2009). 
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter 
methylation in human breast cancer. BMC cancer 9, 217. 
Vriend, L. E., De Witt Hamer, P. C., Van Noorden, C. J., and Wurdinger, T. (2013). WEE1 inhibition 
and genomic instability in cancer. Biochimica et biophysica acta 1836, 227-235. 
Walker, S. R., Nelson, E. A., Yeh, J. E., Pinello, L., Yuan, G. C., and Frank, D. A. (2013). STAT5 
outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. 
Molecular and cellular biology 33, 2879-2890. 
Walker, S. R., Xiang, M., and Frank, D. A. (2014). STAT3 Activity and Function in Cancer: 
Modulation by STAT5 and miR-146b. Cancers 6, 958-968. 
Wang, C., Fan, S., Li, Z., Fu, M., Rao, M., Ma, Y., Lisanti, M. P., Albanese, C., Katzenellenbogen, B. 
S., Kushner, P. J., et al. (2005). Cyclin D1 antagonizes BRCA1 repression of estrogen receptor 
alpha activity. Cancer research 65, 6557-6567. 
Wang, M., Cheng, Z., Tian, T., Chen, J., Dou, F., Guo, M., and Cong, Y. S. (2011). Differential 
expression of oncogenic miRNAs in proliferating and senescent human fibroblasts. Molecular 
and cellular biochemistry 352, 271-279. 
Wang, Y., Tang, N., Hui, T., Wang, S., Zeng, X., Li, H., and Ma, J. (2013). Identification of 
endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with 
acetaminophen-induced hepatotoxicity. Journal of applied toxicology : JAT 33, 1330-1336. 
Weber, M., and Schubeler, D. (2007). Genomic patterns of DNA methylation: targets and 
function of an epigenetic mark. Current opinion in cell biology 19, 273-280. 
112 
 
Weigel, R. J., and deConinck, E. C. (1993). Transcriptional control of estrogen receptor in 
estrogen receptor-negative breast carcinoma. Cancer research 53, 3472-3474. 
Welsh, D. K., Takahashi, J. S., and Kay, S. A. (2010). Suprachiasmatic nucleus: cell autonomy and 
network properties. Annual review of physiology 72, 551-577. 
Weng, L. P., Brown, J. L., and Eng, C. (2001). PTEN coordinates G(1) arrest by down-regulating 
cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase 
activity in a breast cancer model. Human molecular genetics 10, 599-604. 
Widschwendter, M., Apostolidou, S., Raum, E., Rothenbacher, D., Fiegl, H., Menon, U., 
Stegmaier, C., Jacobs, I. J., and Brenner, H. (2008). Epigenotyping in peripheral blood cell DNA 
and breast cancer risk: a proof of principle study. PloS one 3, e2656. 
Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of 
experimental & clinical cancer research : CR 30, 87. 
Xiang, M., Birkbak, N. J., Vafaizadeh, V., Walker, S. R., Yeh, J. E., Liu, S., Kroll, Y., Boldin, M., 
Taganov, K., Groner, B., et al. (2014). STAT3 induction of miR-146b forms a feedback loop to 
inhibit the NF-kappaB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Science 
signaling 7, ra11. 
Xiao, L., Chang, A. K., Zang, M. X., Bi, H., Li, S., Wang, M., Xing, X., and Wu, H. (2014). Induction 
of the CLOCK gene by E2-ERalpha signaling promotes the proliferation of breast cancer cells. 
PloS one 9, e95878. 
Yan, L. X., Wu, Q. N., Zhang, Y., Li, Y. Y., Liao, D. Z., Hou, J. H., Fu, J., Zeng, M. S., Yun, J. P., Wu, Q. 
L., et al. (2011). Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in 
vitro migration and in vivo tumor growth. Breast cancer research : BCR 13, R2. 
Yan, X., Chen, X., Liang, H., Deng, T., Chen, W., Zhang, S., Liu, M., Gao, X., Liu, Y., Zhao, C., et al. 
(2014). miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and 
invasion in breast cancer. Molecular cancer 13, 220. 
Yang, W., Chendrimada, T. P., Wang, Q., Higuchi, M., Seeburg, P. H., Shiekhattar, R., and 
Nishikura, K. (2006). Modulation of microRNA processing and expression through RNA editing by 
ADAR deaminases. Nature structural & molecular biology 13, 13-21. 
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., and Davidson, N. E. (2001). 
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and 
histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer research 
61, 7025-7029. 
Zelinski, E. L., Deibel, S. H., and McDonald, R. J. (2014). The trouble with circadian clock 
dysfunction: multiple deleterious effects on the brain and body. Neuroscience and biobehavioral 
reviews 40, 80-101. 
Zeng, Z. L., Wu, M. W., Sun, J., Sun, Y. L., Cai, Y. C., Huang, Y. J., and Xian, L. J. (2010). Effects of 
the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. Journal of 
biochemistry 148, 319-326. 
Zhang, Y., Eades, G., Yao, Y., Li, Q., and Zhou, Q. (2012). Estrogen receptor alpha signaling 
regulates breast tumor-initiating cells by down-regulating miR-140 which targets the 
transcription factor SOX2. The Journal of biological chemistry 287, 41514-41522. 
Zhang, Z. G., Chen, W. X., Wu, Y. H., Liang, H. F., and Zhang, B. X. (2014). MiR-132 prohibits 
proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochemical 
and biophysical research communications 454, 109-114. 
Zhao, J. J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., and Cheng, J. Q. (2008). 
MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with 
tamoxifen resistance in breast cancer. The Journal of biological chemistry 283, 31079-31086. 
113 
 
Zhao, X., Duan, Z., Liu, X., Wang, B., Wang, X., He, J., Yao, Z., and Yang, J. (2013). MicroRNA-127 
is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast 
cancer cell line MDA-MB-231. Anatomical record 296, 1842-1849. 
Zhu, Y., Stevens, R. G., Hoffman, A. E., Tjonneland, A., Vogel, U. B., Zheng, T., and Hansen, J. 
(2011). Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and 
whole-genome methylation analysis. Chronobiology international 28, 852-861. 
 
 
 
 
 
 
 
114 
 
APPENDIX A 
Supplementary Figures 
 
                 Supplementary Table S1: Acute photoperiod-shifting schedule. 
DAY Light Off 
1 13:30 
2 10:30 
3 07:30 
4 04:30 
5 01:30 
6 22:30 
 
                 Supplementary Table S2: Chronic photoperiod-shifting schedule. 
DAY Lights Off DAY Lights Off 
1 13:30 33 19:30 
2 
10:30 
34 
16:30 
3 
07:30 
35 
13:30 
4 
04:30 
36 
10:30 
5 
01:30 
37 
07:30 
6 
22:30 
38 
04:30 
7-16 Re-entrainment-lights off at 19:30 39-48 
Re-entrainment-
lights off at 01:30 
17 16:30 49 22:30 
18 
13:30 
50 
19:30 
19 
10:30 
51 
16:30 
20 
07:30 
52 
13:30 
21 
04:30 
53 
10:30 
22 
01:30 
54 07:30 
23-32 Re-entrainment-lights off at 22:30 
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Supplementary Figure S1: Breakdown of the circadian disruption tissue extraction 
groups. 
 
 
